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ABSTRACT
Coronary angiogenesis is a natural response to the hypoxia associated with 
cardiovascular disease. Neovascularization may increase blood flow to ischemic tissue 
thereby improving cardiac function. However, in order for new vessel growth to become 
permanent and perfuse the cardiac muscle, these capillaries must mature and be stabilized 
by attachment of smooth muscle cells or pericytes during vascular remodeling.
Therefore, a net increase in perfusion of the cardiac tissue following vascular remodeling 
is the essential goal of therapeutic coronary angiogenesis.
Therapeutic angiogenesis strategies have primarily focused on angiogenic regulatory 
factors, including members of the VEGF and angiopoietin (ANG) families. However, 
temporal expression of these factors in relationship to the growth and remodeling phases 
of angiogenesis has not been established. The current study was designed to characterize 
the transition between angiogenesis and vascular remodeling during tissue remodeling in 
the ischemic murine heart and establish temporal expression patterns of ANG-1, ANG-2, 
Tie2 receptor, VEGF, and the phosphorylated Tie2 receptor within the context of a model 
of vascular growth and remodeling.
Microcauterizer-treatment of the Tie2LacZ transgenic mouse heart to generate a 
myocardial infarction provides a model for histologically defining angiogenic growth and 
remodeling. Whole mount staining of infareted heart tissue in combination with Gomori 
trichrome staining, PECAM labeling, and smooth muscle a-actin labeling of tissue 
sections showed an immediate angiogenic response with a transition to vascular 
remodeling evident at lOd post-treatment. ANG-1, ANG-2, Tie2, and VEGF mRNA 
levels increased at lOd post-infarction in all targets suggesting a coordinate role for the 
ANG and VEGF systems in regulating the remodeling process. However, no temporal 
changes in protein expression were seen in ANG-1, ANG-2, Tie2, phospho-Tie2, and 
VEGF. In addition, immunostaining for ANG-2 demonstrated no difference in 
expression among the time-points. In contrast, immunostaining for phospho-Tie2 
showed different patterns of expression at each of the time-points studied. The results of 
ANG/Tie2 and VEGF expression studies emphasize the potential complexity of 
determining the specific roles of these factors in the adult cardiac vasculature. 
Furthermore, the data suggest that future therapeutic angiogenesis strategies in the heart 
need to focus on both the growth and remodeling phases as critical components of 
effective therapies.
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INTRODUCTION
Cardiovascular Disease
Cardiovascular disease is the leading eause of death in the industrialized world, 
resulting in almost 1 million deaths in the United States alone in 2 0 0 1 The majority of 
deaths result from coronary artery disease, which is characterized by damage to the heart 
tissue due to loss of blood supply. Coronary artery occlusion causes loss of oxygen to the 
myocardium due to reduced blood supply often resulting in myocardial infarction. A 
large portion of the damage to the eardiac tissue is irreversible due to eardiomyocyte 
death. However, reoxygenation of the remaining tissue can prevent further damage. 
Current therapies are designed to either revascularize the cardiac tissue or clear the 
existing bloeked vessels in order to restore oxygen and nutrient delivery to the peri- 
infarct region and prevent disruption of flow to the undamaged tissue.
Therapeutic Angiogenesis
Treatment of individuals suffering from eoronary artery disease typically consists 
of bypass surgery or angioplasty to elear the obstructed vessels. However, for a 
proportion of patients the traditional therapeutic options are either not viable, due to 
diffuse eoronary artery disease or impaired microcirculation, or ineffective, resulting in 
restenosis of the artery. For these individuals, additional treatment strategies are needed. 
One sueh option is therapeutic angiogenesis. Development of eollateral circulation is an 
inherent response to myoeardial hypoxia or ischemia assoeiated with eoronary artery 
disease [1]. Neovascularization, by way of angiogenesis, may aid restoration of cardiac
' American Heart Association. Heart Disease and Stroke Statistics -  2004 Update. Dallas, Tex.: American 
Heart Association; 2003.
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function by increasing perfusion of the affeeted area [2], thereby providing oxygen and 
nutrients necessary for survival of the tissue. However, the natural angiogenic response 
is often insuffieient to effectively perfuse the damaged myocardium. Supplementing the 
innate response through gene or protein therapy is a desirable treatment strategy that has 
gained much focus. Nonetheless, efforts to facilitate or exploit coronary angiogenesis 
have been hindered by insufficient knowledge of the mechanisms by which the body 
stimulates the formation and maturation of new blood vessels.
Angiogenesis
Angiogenesis, the development of new capillaries from the existing vasculature 
[3], is a physiological process that occurs naturally in the female reproductive system and 
in the wound healing response. Pathologieal angiogenesis is evidenced either as 
excessive vascular formation, as seen in tumor formation and progression, 
atheroselerosis, chronic inflammation, and diabetic retinopathy, or inadequate 
neovascularization characteristic of cardiovascular disease and ischemic limb disease.
Angiogenesis is a multi-step process eomprised essentially of growth and 
remodeling phases. Growth of neovasculature oecurs by sprouting of a new vessel from 
an existing vessel. Formation of new vessels necessitates destabilization of the current 
vascular structure, thereby allowing the vaseular components to become receptive to 
additional angiogenic signals. Angiogenesis is often stimulated by hypoxia, growth 
factors or other biochemical signals produced by the surrounding tissue or vascular wall 
cells, and hemodynamic factors, such as shear stress and pressure [4]. The initial 
stimulus triggers degradation of the basement membrane by matrix metalloproteinases
2
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thereby enabling endothelial cell (EC) migration and proliferation. In addition, enhanced 
vascular permeability allows release of plasma proteins, which can form a provisional 
matrix for migration of ECs [5, 6]. The cells assemble into simple chord-like structures 
and acquire a lumen. An alternative method of vessel formation in angiogenesis is 
intussuception; neovascularization occurs by division of an existing vessel by inward 
growth of ECs (for a review see [7]).
In order for the neovasculature to enhance circulation, these newly formed 
capillaries must first undergo remodeling into a branched network of mature, stable 
vessels. Remodeling is distinguished by reorganization of vascular structures in response 
to mechanical and biochemical stimuli [4]. Stabilization and maturation of the vascular 
network occurs by recruitment of pericytes and smooth muscle cells to the endothelial 
eells [8, 9] as well as formation of the new basement membrane. Binding of 
periendothelial cells to the newly formed vessel prevents endothelial cell proliferation 
and migration in addition to making vessels less susceptible to regression [10].
Vaseular regression may occur via endothelial cell apoptosis [7,11] and is 
essentially pruning of the vasculature resulting in the elimination of excess vessels and, 
therefore, a more efficient vascular network. While the signaling mechanisms resulting 
in regression are not understood, physiological factors including perfusion, oxygenation 
state, and shear stress appear to affect vascular regression. Non-perfused vessels and 
those exposed to hyperoxia regress as do those vessels experiencing reduced or absent 
levels of shear stress [10].
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Pericyte/Smooth Muscle Cell and Endothelial Cell Interactions
A key aspect of the remodeling process is the stabilization of vessels of all sizes 
by periendothelial (mural) cells. Pericytes are characterized by a cell body with long 
processes that enable them to embed within the basement membrane and contact ECs 
directly [9]. Detection of pericytes within tissues has proved challenging as a single 
surface marker does not usually detect all sueh cells. In addition, markers, such as 
platelet derived growth factor (PDGF)-P and high molecular weight-melanoma- 
associated antigen, that characteristically detect activated pericytes do not detect the cells 
in quiescent tissues [12]. Electron microscopy provides the most reliable means of 
detecting pericytes embedded within the basement membrane [13].
Currently, mural cells are believed to play a role in inhibiting EC proliferation 
[14,15] and migration as well as production of extracellular matrix components to 
stabilize vessels. Vessels lacking periendothelial coverage are more prone to regression 
[16]. Furthermore, the number and structure of pericytes varies among tissues and 
vessels suggesting periendothelial eells may assist ECs in acquiring distinct functions 
depending on the needs of the vascular bed [9]. In addition to their structural role, 
pericytes and smooth muscle cells provide molecular signals via growth factors and 
cytokines that influence function of the vascular network.
Regulation o f Angiogenesis & Vascular Remodeling
Regulation of angiogenesis and vaseular remodeling is known to he a multi- 
factorial process involving a precise balance between positive and negative endogenous 
regulators. Each step in the process must be tightly controlled to prevent excessive
4
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vascular growth. For example, activating signals stimulate the proliferation and 
migration of ECs; these actions are eounter-balanced by inhibitory signals. In fact, some 
naturally occurring inhibitors of angiogenesis induce EC apoptosis [17]. In an 
unperturbed system, proper regulation results in quiescent vessels.
Angiogenic factors are believed to be the primary regulators of the angiogenic 
process. Among the most prominent are vascular endothelial growth factor (VEGF) and 
angiopoietin (ANG)-1 and -2. VEGF and fibroblast growth factor (FGF)-2 have 
generated a great deal of interest due to their ability to regulate a number of distinct 
angiogenic events. A number of additional factors, which may play a role in the 
angiogenic process, have also been identified suggesting the signaling pathways for 
angiogenesis are likely to be many and complex. Furthermore, these factors are proposed 
to be tightly regulated temporally and spatially resulting in a functional vascular network 
[18].
Vascular Endothelial Growth Factor
VEGF was first described as both a potent endothelial cell mitogen [19, 20] and a 
vascular permeability factor [21,22]. Since its initial characterization a total of five 
VEGF family members have been isolated, several of whieh consist of multiple isoforms. 
VEGF-A (VEGF) is the most well charaeterized and highly studied member of the 
family.
VEGF is a 34-46 kDa homodimeric glycoprotein [21]. Alternative splicing 
produces four isoforms of murine VEGF: VEGF-120, -144, -164, and -188. Exons 6 and 
7, lacking in VEGF-120, encode heparin and heparan proteoglycan binding domains.
5
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VEGF-120 is a freely soluble fomi of the factor, whereas the remaining isoforms may 
bind to the cell surface or extracellular matrix thus restricting their bioavailability.
VEGF-164 is the predominant isoform measured in many tissues and cells; however 
VEGF-120 and VEGF-188 are also commonly detected [23].
A number of different cell types, including endothelial cells, fibroblasts, smooth 
muscle cells, and macrophages, produce VEGF leading to a primarily paracrine mode of 
action. VEGF binds to endothelial tyrosine kinase receptors, VEGF receptor-1 (Flt-1) 
and VEGF receptor-2 (Flk-l/KDR). Activation of either receptor by the VEGF ligand 
results in homo-dimerization and autophosphorylation on tyrosine residues. Binding of 
VEGF to Flk-1 stimulates EC proliferation in addition to mediating increased vascular 
permeability. In addition, VEGF promotes endothelial survival by inhibiting apoptosis 
through up-regulation of Bel-2 and survivin [24, 25]. Generation of VEGF null mice has 
established VEGF as a critical mediator of the early stages of vascular development. In 
addition to impaired blood vessel development in VEGF null mice, embryos 
heterozygous for the VEGF allele exhibit a lethal phenotype, emphasizing a critical dose- 
dependence on the factor during embryonic vessel development [26, 27].
Hypoxia has been shown to mediate VEGF expression by either stimulating 
transcription [28] or increasing stability of the message [29, 30]. The transcriptional 
regulator hypoxia inducible factor (HlF)-l has been shown to bind and stimulate 
transcription of VEGF [31]. In addition, TGF-P, interleukin-1 and interleukin-6 have 
been shown to up-regulate VEGF in vitro [32-34].
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Tie2
Tie2 is a transmembrane tyrosine kinase receptor expressed predominantly in the 
vascular endothelium and on some hematopoietic cells [35, 36]. Tie2 was first isolated 
by RT-PCR and identified as a novel receptor tyrosine kinase (RTK) based on its amino 
acid sequence [35] and structural homology with the RTK gene family [37], Enzymatic 
characterization of human Tie2 and phosphorylated (phospho-) Tie2 demonstrated that 
autophosphorylation occurs first at Y992 of the activation loop; subsequent 
autophosphorylation of the C-terminal tail occurs at Y 1108 [38]. Additional evidence 
suggests that Y1101 of Tie2 may be important to the biological role of the receptor. 
Decreased tyrosine phosphorylation has been demonstrated in the tyrosine-to- 
phenylalanine mutant Y1 lOlF [39]. In addition, intact Y1101 is required for 
phosphorylation and activation of Akt and activation of PI3-kinase [39], whieh has been 
shown to regulate EC survival [40]. A study mapping the interactions of putative Tie2 
phosphorylation sites with known RTK targets demonstrated interactions with murine 
Y1100, Y1106, and Y1111 (corresponding to human Y1101, Y1108, and Y1112) [41]. 
Furthermore, a potential role for murine Y897 in the negative regulation of Tie2 has been 
suggested [37].
While the downstream signaling pathways responsible for the vascular effects of 
Tie2 are not well understood, ANG-1 and ANG-2 have been identified as ligands for the 
receptor. Binding of ANG-1 to Tie2 induces dimerization and autophosphorylation of 
the receptor [42]. Expression of phosphorylated Tie2 has been observed in both active 
and quiescent ECs in numerous adult tissues, suggesting constitutive activation, and 
therefore a possible role in vascular maintenance [43]. Furthermore, investigation of
7
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Tie2 null mice has suggested that the reeeptor is critical for proper development of 
mature vessels. Tie2 knockout mice die at embryonic day 9.5-10.5 with deficits in 
remodeling of the initial capillary plexus into a more diverse and complex vascular 
network [44].
Evidence for regulation of Tie2 by hypoxia is contradictory. Prolonged exposure 
(48 h) of rats to hypoxie air resulted in a deerease in both mRNA and protein levels in the 
heart [45]. However, Tie2 expression inereased in human ECs in vitro [46] and remained 
stable in cultured bovine mierovascular ECs (BMECs) [47] following hypoxic treatment; 
in addition, Tie2 expression was unaffected by VEGF treatment in BMECs [47]. Up- or 
down-regulation of Tie2 by ANG-1 or ANG-2 has not been elearly demonstrated.
Angiopoietin-1
Angiopoietin-1 was the first of a family of four angiopoietins to be isolated as a 
ligand for Tie2. ANG-1 is an -70 kDa, secreted glycoprotein that organizes into higher- 
order multimers. Expression of ANG-1 has been loealized to pericytes, ineluding those 
expressing markers of aetivation, and smooth muscle eells [12], thus suggesting a 
paracrine meehanism of action. Similar to Tie2, expression of ANG-1 mRNA has been 
noted in numerous adult tissues ineluding those involved in vascular remodeling in a 
healthy adult, sueh as uterus and ovary, and those considered quieseent, sueh as heart and 
brain [48].
Initial characterization of ANG-1 showed it to be non-mitogenic, unlike 
previously identified angiogenie faetors, sueh as VEGF [42]. However, additional in 
vitro studies have suggested several potential roles for ANG-1 in the vaseulature.
8
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Treatment of cultured ECs with ANG-1 results in a chemotactic response of the cells 
toward ANG-1 [49, 50] that appears to be mediated via the PI3-kinase pathway [50] and 
in tubule formation [51]. Furthermore, a role has been established for ANG-1 in the 
promotion of EC survival [40, 49-52]. Stimulation of ECs by ANG-1 results in an 
elevation of the anti-apoptosis factor, Survivin, via a PI3-kinase/Akt-dependent 
mechanism [52].
In vivo, the phenotype of the ANG-1 null mouse first led to the suggestion that 
ANG-1 may have a role in the remodeling process. Embryos lacking ANG-1, or Tie2, 
develop a seemingly conventional primary vasculature, which then fails to undergo 
further remodeling, suggesting ANG-1 is involved in later stages of vaseular 
development [53]. In addition, ANG-1 -/- embryos exhibit poor endothelial 
cell/periendothelial support cell interactions when compared to wild-type embryos. A 
postnatal cornea micropocket assay studying the effect of ANG-1 in combination with 
VEGF showed abundant periendothelial cells when ANG-1 was administered with VEGF 
but few such cells when VEGF was given alone [54]; the cornea micropocket assay 
allows assessment of neovascularization directly stimulated by cytokine-containing 
pellets implanted beneath the cornea. This evidence supports the view that activation of 
Tie2 by ANG-1 may initiate the release of faetors that recruit perivascular support cells to 
the remodeling vasculature [44, 53].
While the downstream signaling pathways are not yet known, ANG-1 also 
appears to play a key role in inhibiting the inflammatory response and mediating the 
reduction of vascular permeability in vitro and in vivo [55-57]. Over-expression of ANG- 
1 reduces inflammation associated with VEGF-induced neovascularization [56, 57].
9
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Additionally, ANG-1 is believed to act as an anti-permeability factor, reciprocal to 
VEGF. Transgenic over-expression of VEGF has been shown to result in leaky vessels, 
which can he stabilized by simultaneous over-expression of ANG-1 [57]. In vitro 
examination of human umbilical vein ECs treated with ANG-1 suggests that the anti- 
permeability characteristics of the factor are likely to be mediated by regulation of 
endothelial cell junctional complexes [55].
Additional evidence strongly suggests that the role of ANG-1 in vascular 
remodeling is due to binding and activation of Tie2 by ANG-1. Initial characterization of 
ANG-1 showed that tyrosine phosphorylation of Tie2 induced by the ligand could be 
inhibited by addition of soluble Tie2 (sTie2) [42]. In addition, in vitro treatment of 
endothelial cells with sTie2 blocks migration, tubule formation, and the anti-apoptotic 
effect induced by ANG-1 [40,49, 51]. In the cornea micropocket assay, modulation of 
VEGF-induced neovascularization by ANG-1 is abolished by the addition of sTie2 [54].
Little is known about the regulation of ANG-1. Hypoxia has been shown to 
down-regulate ANG-1 in rat glioma cells in vitro [58] and in rat heart tissue after a 48 h 
hypoxic exposure [45] but have no effect on ANG-1 expression in cultured bovine 
mierovascular endothelial cells (BMECs) [47]. Furthermore, ANG-1 expression remains 
stable after VEGF exposure in BMECs [47].
Angiopoietin-2
ANG-2 is a ligand for Tie2 as well, acting as a natural antagonist to ANG-1 in the 
vascular system. Similar to ANG-1, ANG-2 is a non-mitogenic, secreted glycoprotein, 
which forms homodimers. In vitro, ANG-2 expression has been identified in numerous
10
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endothelial cell lines [12,49, 59]. However, contrary in vivo evidence suggests that 
cellular localization of ANG-2 may vary by tissue or experimental system; ANG-2 has 
been identified in endothelial cells of glioma tumors [60] but also in pericytes and smooth 
muscle cells of the developing aortic branches in the mouse [48, 61]. Examination of 
murine tissues by in situ hybridization and Northern blot analyses has shown ANG-2 
expression at sites of vascular remodeling, including ovary, placenta, uterus, and corpus 
luteum [48].
ANG-2 and ANG-1 have demonstrated comparable binding affinity for the Tie2 
reeeptor [42,48]. However, a fourfold to eightfold molar excess of ANG-2 was shown to 
considerably block ANG-1 mediated activation of the Tie2 receptor in a human 
endothelial hybrid cell line [48] thus resulting in the conclusion that ANG-2 serves as an 
antagonist for the receptor. In contrast to ANG-1, ANG-2 does not elicit a chemotactic 
response in ECs [49]. Furthermore, activation of Tie2 is not evidenced when ECs are 
treated with ANG-2 for short duration or at concentrations comparable to those at which 
ANG-1 is capable of inducing Tie2 phosphorylation. However, additional in vitro data 
have shown that prolonged EC exposure to ANG-2 [62], administration of ANG-2 at high 
concentration [63], and treatment of non-endothelial cells ectopically expressing Tie2 
[48] results in phosphorylation of the Tie2 receptor suggesting a potentially complex role 
for ANG-2 in the vaseular system.
The phenotype of the ANG-2 transgenie mouse is reminiscent of that of the ANG- 
1 and Tie2 knockout mice providing additional support for the proposal that ANG-2 
serves as an antagonist in the vascular system [44,48, 53]. Generation of the ANG-2 null 
mouse however, provided further evidence that the role of ANG-2 may be system and
11
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context dependent. The ANG-2 knockout proceeds through vascular development 
normally but undergoes impaired vascular remodeling of the neonatal eye. In addition, 
evidence suggests that ANG-2 acts as an agonist in the lymphatic system with the ANG-2 
knockout exhibiting abnormal organization and function of the lymphatic vasculature, 
which can be recovered by treatment with ANG-1 [61].
In contrast to ANG-1, ANG-2 is thought to act in concert with VEGF, promoting 
angiogenesis by destabilizing vessels through disruption of endothelial cell -  pericyte 
interactions [64]. Coexpression of ANG-2 and VEGF has been noted at sites of 
angiogenesis, including the corpus luteum and vascularized tumors [48, 65].
Furthermore, in pupillary membrane and comeal micropocket models, ANG-2 has been 
shown to have a proangiogenic effect when administered with VEGF [66, 67].
Up-regulation of ANG-2 mRNA is stimulated by a variety of stimuli including 
hypoxia, VEGF, basic fibroblast growth factor, and tumor necrosis factor-a [47, 59, 68]. 
VEGF treatment in vitro increases the rate of ANG-2 transcription with an accompanying 
increase in protein synthesis [47]. Suggesting a feedback mechanism, ANG-2 is down- 
regulated by ANG-1 and ANG-2 itself [59]. A decrease in ANG-2 mRNA also results 
from exposure to TGF-p [59]. Furthermore, hypoxic regulation of ANG-2 in vivo has 
been shown to vary by organ with a decrease in ANG-2 mRNA in the heart following 
prolonged hypoxia [45].
Gene and Protein Angiogenic Therapy
Existing therapeutic angiogenesis strategies have focused primarily on the VEGF 
and fibroblast growth factor (FGF) families, due largely to their demonstrated ability to
12
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stimulate angiogenesis in animal models and in vitro. Currently, greater than twenty 
clinical trials utilizing a member of the VEGF or FGF families are underway. Use of a 
single factor is based on the assiunption that administration of the gene or protein will 
trigger all downstream signaling necessary for growth and establishment of the 
neovasculature. The results of many early trials have been promising, demonstrating 
vascular formation, increases in perfusion, and improvements in objective measures of 
function. However, side effects such as edema [69] or hypotension [70] as well as the 
question of whether these factors are capable of stimulating long-term neovascularization 
have led investigators to hypothesize that a single angiogenic factor may be insufficient 
to induce a stable, functional vasculature. Additional molecules, which have been 
recently considered, are HIF-la and ANG-1. HIF-la is a transcriptional activator known 
to stimulate VEGF expression. Generation of HIF-la transgenic mice, using an altered 
form of the gene, demonstrated vascular formation without the edema and inflammation 
associated with the VEGF transgenic mouse [71]. In addition, in a hindlimb ischemia 
model, induced by dissection and removal of the femoral artery, sequential administration 
of ANG-1 naked DNA followed by VEGF resulted in improved vascularity, including an 
increase in the number of vessels positive for a smooth muscle marker, without VEGF- 
mediated edema [72]. This evidence suggests an upstream molecule capable of initiating 
multiple angiogenic factors or sequential administration of unique angiogenic factors may 
stimulate a more complete vascular response.
Limitations o f Existing Models for the Study o f Angiogenesis and Vascular Remodeling 
Development of effective angiogenic therapies will require understanding of the
13
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complex mechanisms regulating the entire angiogenic process from stimulation of growth 
through stabilization and maturation of a functional vasculature. Existing experimental 
models attempt to establish various growth factors as regulators of the angiogenic process 
but often fail to place these angiogenic factors within the context of a defined model for 
vascular growth and remodeling. A recent study in which hypoxia was induced in the rat 
heart for various lengths of time followed by 24 h of reoxygenation demonstrated 
differential expression of VEGF, the VEGF receptors, the angiopoietins, and Tie 
receptors when compared to normoxie control [73]. However, references to the “initial” 
and “later stages of the early angiogenic process” were not defined temporally or 
histologieally, thereby weakening the conclusions to be drawn from the protein data. 
Determination of temporal expression patterns of angiogenic factors in a cardiac model in 
which the morphological characteristics associated with vascular growth and remodeling 
have been described will facilitate the refinement of therapeutic strategies for 
cardiovascular disease.
Tie2LacZ Mouse Model
A key factor in determining the regulatory mechanisms of angiogenesis and 
vascular remodeling is the ability to assess these phases within an in vivo system. 
Tie2LacZ transgenic mice provide a model for histologically defining angiogenic growth 
and remodeling. Specific expression of the LacZ gene in the vascular endothelium via 
the Tie2 promoter [74] allows qualitative assessment of morphological changes in the 
vasculature by whole mount P-galactosidase staining of the tissue. Microcauterizer- 
treatment of the heart to generate an infarct serves as a means of stimulating a complete
14
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angiogenic response comprised of both growth and remodeling phases. In a prior study, 
assessment of microcauterizer-wounded tissue at 7 days post-treatment revealed an 
apparently avascular area when perfused with fluorescein-dextran [75]. However, the 
Tie2LacZ model allows detection of an initial capillary plexus around the wound as early 
as 1 day post-treatment. In addition, tissue remodeling associated with the 
microcauterizer-generated infarct is consistent with that evidenced in a murine model of 
myocardial infarction induced by permanent left anterior descending coronary artery 
occlusion [76]. Microcauterizer stimulation of angiogenesis in the Tie2LacZ transgenic 
mouse provides a model for the study of vascular growth and remodeling in addition to 
the characterization of the regulatory pathways mediating these phases.
Proposed Model fo r  Regulation ofAngiogenesis and Vascular Remodeling
The ANG and VEGF systems are strong candidates for distinct roles in the 
regulation of vascular growth and remodeling. The model shown in Fig. 1 summarizes 
the proposed roles for the ANG/Tie2 and VEGF systems in coordinately regulating the 
growth and later stabilization of the vasculature in response to myocardial ischemia; these 
roles are described in detail below.
15
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Figure 1. Model of molecular regulation of growth and remodeling phases of 
coronary angiogenesis. (Adapted from Yaneopoulos et al [18])
Co-expression of ANG-2 and VEGF has been documented at sites of vascular 
invasion, including the corpus luteum and vascularized tumors, whereas the presence of 
ANG-2 in the absence of VEGF was associated with vascular regression [48, 64]. These 
observations have led to the hypothesis that ANG-2 and VEGF together may be involved 
in destabilizing the existing vasculature. ANG-2 is believed to bind Tie2 inhibiting the 
stabilizing influence of ANG-1 and thereby facilitating sprouting of new vessels in the 
presence of VEGF. Additional support for this role was provided by the study of these 
factors in an in vivo comeal micropoeket assay. Administration of ANG-2 in 
combination with VEGF was pro-angiogenic, causing an increase in the length and 
circumference of newly formed vessels when compared to VEGF alone [54]. 
Furthermore, injection of ANG-2 in an in vivo pupillary membrane model stimulated a 
vascular response, which included increased capillary diameter, EC migration, and 
sprouting; however, eo-injection of soluble VEGF receptor-1 and ANG-2 resulted in
16
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increased endothelial apoptosis suggesting the pro-angiogenic effect of ANG-2 was 
dependent on endogenous VEGF [66]. Animal models of myocardial ischemia have also 
demonstrated coincident increases in ANG-2 and VEGF following either repetitive [77] 
or permanent [78] occlusion of the left anterior descending artery.
Numerous in vitro and in vivo studies have documented the roles of VEGF in 
vascular formation, especially endothelial cell proliferation and migration. In addition, 
the importanee of VEGF in neovascularization of ischemic tissue is suggested by analysis 
of ischemic limb [79] and ischemic cardiac tissue [77, 78, 80], which have demonstrated 
elevated levels of VEGF, and its receptor Flk-1, when compared to non-ischemic regions. 
Vascular formation has also been observed as an outcome in gene and protein therapies 
utilizing VEGF [69, 72, 81-85].
While ANG-2 and VEGF are thought to initiate destabilization of the existing 
vasculature and formation of new vessels, the Tie2 agonist, ANG-1, is believed to 
promote maturation and stabilization of the neovasculature. The stabilizing effect of 
ANG-1 via activation of the Tie2 receptor was first suggested by the phenotypes of the 
ANG-1 and Tie2 mice; embryos null for either molecule exhibited poor perivascular 
support cell interactions when compared to their wildtype counterparts [44, 53].
In addition, co-administration of ANG-1 and VEGF in the postnatal cornea micropoeket 
assay showed abundant periendothelial cells when ANG-1 was administered with VEGF 
but few such cells when VEGF was given alone [54].
While in vitro data have suggested roles for ANG-1 in EC migration and tube 
formation [49-51], in vivo support for those functions has been limited to the stimulation 
of neovascularization in hindlimb ischemia and comeal micropoeket models upon co-
17
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expression of ANG-1 and VEGF [54, 72, 86]; the in vivo or ex vivo effects of ANG-1 on 
EC migration and/or tube formation have not been studied. In addition, studies have 
shown constitutive expression of ANG-1, similar to Tic2, in the heart and brain with no 
change in expression following myocardial infarction or middle cerebral artery occlusion 
[77, 87],
The most dramatic role for ANG-1 demonstrated in postnatal in vivo models is 
that of an anti-permeability factor. Transgenic over-expression of ANG-1 in the skin and 
heart has resulted in suppression of vascular leakage induced by simultaneous over­
expression of VEGF [57, 88]. Furthermore, administration of exogenous ANG-1 has also 
been shown to counter vascular permeability resulting from blockage of platelet derived 
growth factor (PDGF) signaling [89]. In vitro data suggests that ANG-1 supports 
localization of cell adhesion molecules into endothelial cell junctions and stabilizes 
junctions thereby decreasing permeability [55]. This role is believed to be facilitated by 
stabilization from perivascular cells. In addition, previous models have suggested that 
binding of ANG-1 to Tie2 may stimulate the release of factors responsible for the 
recruitment of mural cells to the immature vasculature [44, 53] thereby stabilizing the 
vessels.
Understanding the regulation of angiogenesis and vascular remodeling in the adult 
heart will facilitate development of effective therapeutic angiogenic strategies. Based on 
the evidence described, the ANG and VEGF systems are candidates for critical roles in 
the regulatory process. Furthermore, the putative stabilizing effects of ANG-1 are likely 
to be mediated via phosphorylation of the Tie2 receptor. Assessment of the 
phosphorylation state of Tie2 in microcauterizer-treated murine heart tissue will allow
18
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further understanding of the role of the ANG-Tie2 system in the vascular growth and 
remodeling processes. The goal of this project is to advance development of gene 
therapies by further establishing the roles of these faetors within the context of a 
morphologically characterized model of vaseular growth and remodeling. The research 
described will test the hypothesis that VEGF and ANG-2 will be up-regulated during 
the growth phase of angiogenesis while elevation of ANG-1 and Tie2 and an increase 
in phosphorylated Tie2 receptor will occur later, coincident with remodeling.
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The current study addressed the following Specific Aims:
Specific Aim I.
Specific Aim II.
Specific Aim III.
Establish the Tie2LaeZ transgenic mouse as a model for in vivo 
study of angiogenic growth and remodeling in the ischemic murine 
heart.
Characterize the temporal expression patterns of known angiogenic 
regulatory proteins as associated with the growth and remodeling 
phases of coronary angiogenesis.
Demonstrate altered phosphorylation of Tie2 receptor in heart 
tissue actively undergoing vaseular growth and remodeling that 
occurs following microcauterizer wounding.
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MATERIALS and METHODS
Animals and Treatment Groups
This study conforms to the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIK Publication No. 85-23, revised 1996). 
Tie2LaeZ transgenic mice on a FVB/N baekground were initially obtained from Jackson 
Laboratories (Bar Harbor, ME, USA). They were raised and maintained at The 
University of Montana according to Institutional Animal Care and Use (lACUC protocol 
#ACC-005-02) and Public Health Service standards. The mice were housed in 
microisolation cages under speeifie pathogen free conditions with constant temperature 
and humidity. They received food and water ad libidum and had a controlled 12 h 
light/dark cycle. Animals were genotyped by polymerase chain reaction for the 
Tie2LacZ transgene^. All miee positive for the transgene were hemizygous based on 
parental genotypes. The mice were divided into three treatment groups; non-surgical 
control (NSC), surgical control (SC) and microcauterizer-infarcted (MC). Each group 
was composed of Tie2LacZ transgenie mice at 10-12 weeks of age. Within the SC and 
MC groups, animals were divided into five sub-groups: 1,4, 7, 10, and 14d post­
treatment. The ‘n ’ number and gender of mice assigned as well as the time-points 
assessed for eaeh experimental study is shown in Table 1. A total (including the NSC 
group) of 11 sub-groups was analyzed.
Microcauterizer Treatment
Surgery was carried out similar to Chiotti et al [75]. Mice were anesthetized with an
 ̂The Jackson Laboratory (http://www. jax.org)
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Table 1. Summary of experimental groups. Non-surgical control mice were studied in 
all experiments, as were surgieal control and microcauterizer-treated mice at each of the 
time-points listed.
Experimental Technique n Gender Time-points
Whole mount histology 3-5 Mixed Id, 4d, 7d, lOd, 14d
Immunohistochemistry 3-5 Mixed 4d, 7d, lOd, 14d
Real-time RT-PCR 8 Female Id, 4d, 7d, lOd, 14d
Western Blot & ELISA 8 Male Id, 4d, 7d, lOd 14d
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intraperitoneal injection of avertin [90] (0.015 cc/g body weight), intubated orally using a 
22 gauge cannula and ventilated (Harvard Instruments, Boston, MA) with 25 cc/min 
oxygen-supplemented air. Subsequently, the thorax was shaved and swabbed with 
betadine and a mediolateral incision made between the fifth and sixth ribs to expose the 
heart. For MC treatment a microcauterizer was used to make a small infarct 
approximately 1.5-2 mm in diameter on the left ventricle near the apex of the heart. The 
chest wall was sealed with one to two sutures and the pneumothorax was relieved with a 
22 gauge eannula and 5 cc syringe. Wound clips closed the skin incisions and the mice 
were allowed to recover on a warming pad. Surgical control animals received 
thoracotomy with a touch to the heart with the unheated microcauterizer. Survival rate in 
both groups was greater than 90%. Following treatment, mice recovered for 1,4, 7, 10, 
or 14 d after which they were sacrificed and the heart harvested. Animals in the NSC 
group received no anesthesia and underwent no surgery or treatment.
Whole Mount Histology
Mice were anesthetized with avertin and perfused through the left ventricle with 0.1 M 
phosphate buffered saline pH 7.4 (PBS) followed by PLP fixative (4% paraformaldehyde, 
0.12 M L-lysine hydrochloride, and 15.6 mM Na-m-periodate); care was taken to avoid 
the infaret when inserting the perfusion needle. Following perfusion, the heart was 
removed and transferred to Bluo-Gal stain solution (4.9 mg Bluo-Gal (5-bromo-3- 
indolyl-B-D-galactopyranoside; Diagnostie Chemicals Limited, Prince Edward Island, 
Canada), 0.1 ml N,N-dimethylformamide, 10 ml PBS, 1 mM MgCl2, 3 mM K4Fe(CN)e). 
Hearts were stained overnight at 37°C with gentle agitation and minimal light exposure.
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After satisfactory staining was achieved (8-12 h), hearts were rinsed in PBS twice for 5 
min each. The tissue was examined and photographed as a whole mount with an 
Olympus SZ-STS Zoom Stereo Microscope (Olympus America, Melville, NY).
Fixation and Processing o f Tissue fo r  Histology
Mice were anesthetized with avertin and perfused for 10 min through the left ventricle 
with 0.1 M Tris buffer, pH 7.4. Following perfusion, hearts were removed, cut into three 
equal thickness cross sections from apex to base and post-fixed in Tris-buffered zine 
fixative (2.8 mM ealcium aeetate, 22.8 mM zine aeetate and 36.7 mM zine chloride in 0.1 
M Tris buffer, pH 7.4) [91] for 12-24 h at room temperature (RT). Tissue was then 
processed through a graded alcohol series, methyl salicylates, paraffin-embedded, and 
sectioned at 5 pm. Tissue was mounted as 1 in 10 series onto Superfrost® Plus slides 
(VWR Scientific, West Chester, PA). Slide-mounted sections were deparaffmized and 
rehydrated prior to immunohistochemistry and trichrome staining.
PECAM/Smooth Muscle a-Actin Immunostaining and Gomori Trichrome Stain 
Following rehydration, slides were rinsed in Tris buffer pH 7.4 (Tris) and blocked for 20 
min with 4% normal goat serum in 0.1 M Tris buffer pH 7.4 with 1% bovine serum 
albumin and 0.1% sodium azide (TAB). All antibodies were diluted in TAB and rinses 
carried out in Tris. Slides were incubated overnight at 4°C with biotinylated anti- 
PECAM (1:50; Pharmingen, San Diego, CA; 553371). Slides were rinsed and incubated 
for 1 h at RT with streptavidin 488 (T.500; Molecular Probes, Eugene, OR; SI 1223). 
Slides were then rinsed and incubated 1 h at RT in the dark with anti-smooth muscle
24
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
alpha actin (SMA; 1:150; Dako, Carpinteria, CA; M0851). Following a Tris rinse, slides 
were incubated for 1 h at RT with goat anti-mouse 546 (1:1500; Molecular Probes;
A l 1003), rinsed sequentially in Tris, ddH20, and PBS followed by coverslipping with 
PBS. Using an automated stainer (TbermoSbandon, Pittsburgh, PA) an alternate series of 
serial sections was rinsed with dH2 0 , fixed in 10% formalin, rinsed with dH2 0 , and 
stained with Gomori tricbrome following the TbermoSbandon protocol to delineate the 
infarct region in MC-treated tissue.
Angiopoietin-2 andphospho-Tie2 Immunostaining
Immunostaining was performed on alternate series of serial sections previously mounted. 
All antibodies were diluted in TAB and rinses carried out in Tris buffer pH 7.4 or Tris 
with 1% bovine serum albumin (Tris/BSA). Following rebydration, endogenous 
peroxidase was blocked by 0.3% H2O2/40% MeOH in PBS overnight at RT. Slides were 
rinsed and blocked with 4% normal goat serum in TAB for 20 min. Slides were 
incubated overnight at4°C with anti-Ang2 (1:500; Cbemicon, Temecula, CA; AB3121) 
or anti-pbospbo-Tie2 (1:8000; Oncogene Research Products, San Diego, CA; PC449). 
Slides were rinsed in Tris followed by Tris/BSA and incubated for 1 b at RT with 
biotinylated goat anti-rabbit secondary (1:400; Vector Laboratories, Burlingame, CA). 
Slides were rinsed and incubated for 1 b at RT with Vector Elite ABC avidin-biotin 
complex (Vector Laboratories) followed by visualization with 3-3’ diaminobenzidine 
(DAB; Sigma). Slides were dehydrated and coverslipped using DPX mounting medium 
(BDH Limited, Poole U.K.).
25
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Preparation o f Tissue for ELISA and Western Blot Analysis
Mice were sacrificed by cervical dislocation. Following removal and bisection of the 
heart, a 3 mm puneh of tissue ineluding the wound site was isolated and snap-frozen in 
liquid nitrogen; tissue from a similar region of the heart was harvested from NSC and SC 
miee. Tissue punehes were homogenized in RIPA lysis buffer [92] containing 20 mM 
EDTA and 1 Complete Protease Inhibitor tablet (Roche, Indianapolis, IN; 1697498) per 
50 ml IX buffer. BCA protein assays (Pierce, Rockford, Illinois, USA) were performed 
on individual samples to determine total protein (TP). Within eaeh sub-group (including 
NSC), two tissue samples were pooled by equivalent amounts of protein. A second 
protein assay was run on the pooled supernatant to quantitate TP for use in ELISA and 
Western blot analysis. The experiment was performed in quadruplicate for a total of 
eight animals per sub-group. For the NSC sub-group, a second set of pooled protein 
comprised of equivalent amounts of TP from all eight animals was prepared for use in 
Western Blotting.
ELISA
VEGF ELISA (R&D Systems, Minneapolis, MN; MMVOO) was performed according to 
the manufacturer’s instructions using 100 pg TP. Each two-sample pool (including NSC) 
was run in duplicate. Plates were analyzed and VEGF protein (pg/ml) results obtained 
using SOFTmax® PRO software (Molecular Devices, Sunnyvale, CA). The experiment 
was carried out in duplicate.
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Western Blot and Densitometry
Protein samples were boiled in Laemmli Sample Buffer (BioRad, Hercules, CA;
1610737) for 5 min, and 30 pg TP from each two-sample pool was run on reducing 10% 
SDS-PAGE gels (Cambrex Bio Science, Walkersville, MD; 58502). The NSC 8-sample 
pool was run on every gel for purposes of gel-to-gel standardization. Biotinylated protein 
standards (Cell Signaling, Beverly, MA) and prestained protein standards (BioRad) were 
run on each gel. Separated proteins were transferred to Hybond-P PVDF membrane 
(Amersham Biosciences, Piscataway, NJ) in transfer buffer (BioRad; 1610771) with 
0.05% SDS (ANG-2, Tie2) or without SDS (ANG-1, phospho-Tie2) for 5 h at lOOV. 
ANG-1, ANG-2, and Tie2 blots were blocked in 5% dry milk/TBST (10 mM Tris base, 
150 mM NaCl, 0.2% Tween-20 pH 8.0) for 1.5 h at RT while phospho-Tie2 blots were 
blocked in 10% bovine serum albumin (BSA)/TBST. Blots were rinsed in TBST once 
for 15 min and two times at 5 min each. Primary antibodies against ANG-1 (1:1000; 
R&D Systems; AF923), ANG-2 (1:250; Cbemicon), and Tie2 (1:250; Pharmingen, San 
Diego, CA; 557039) were diluted in 5% dry milk/TBST while phospho-Tie2 (1:1000; 
Oncogene) was diluted in 10% BSA/TBST. Blots were incubated with their respective 
primary antibody overnight at RT. Following TBST rinses, ANG-2 and phospho-Tie2 
immunoblots were incubated with peroxidase-conjugated anti-rabbit secondary antibody 
(1:5000; Vector Laboratories) and Tie2 immunoblots with peroxidase-conjugated anti­
mouse secondary antibody (1:5000; Vector Laboratories) for 1 h at RT. ANG-1 
immunoblots were incubated with biotinylated anti-goat secondary (1:5000; Vector 
Laboratories) for 1 h followed by incubation with horseradish-peroxidase streptavidin 
(1:2000; Vector Laboratories) for 1 h. Proteins were detected with enhanced
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chemiluminescent detection (ECL) reagents (Amersham) and images captured using a 
VersaDoc model 3000 system (BioRad). Bands were quantitated with local background 
subtraction using Quantity One software version 4.3.0 (BioRad). Quantitative data was 
normalized to NSC prior to data analysis.
Real-time RT-PCR
Mice were sacrificed and tissue harvested and snap-frozen as for protein analysis. Total 
RNA was isolated from each tissue punch using the Qiagen RNeasy® Mini Kit (Qiagen, 
Valencia, CA; 74104) in the method described by the manufacturer. Real-time RT-PCR 
was used to quantitate relative levels of ANG-1, ANG-2, Tie-2, and VEGF mRNA. 
Real-time RT-PCR was carried out using the ABI PRISM® 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA). Murine growth factor sequences were 
obtained from NCBI, and PCR primers and dual-labeled probes (Table 2) designed using 
Primer Express® Version 1.5 (Applied Biosystems). HPRT served as endogenous control 
and was assayed separately from target amplicons. An assay speeifie synthetic 
oligonucleotide encompassing the entire length of the amplicon was diluted in lOOng/pl 
tRNA/DEPC-HaO and used in the creation of a standard curve for each transcript. All 
samples were diluted and DNAse-treated prior to reverse transcription. Each sample was 
assayed in triplicate plus one no amplification control without reverse transcriptase. For 
each replicate, the reverse transcription reaction mixture (10 pi) contained Ix reverse 
transcriptase buffer, 500 pM deoxynucleotides, 400 nM assay-specific reverse primer, 
lOU reverse transcriptase, and 4 pi DNase-treated sample RNA (12.5 ng/pl). Cycling 
conditions were as follows: 25°C for 10 min, 48°C for 30 min, and 95°C for 5 min. Real-
28
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 2. Real-time RT-PCR Primer and Probe Sequences
Target Forward Primer, Dual-labeled Probe, Reverse Primer
ANG-1 Fwd: 5'-GCTTGATCTTACACGGTGCTG
Probe: 5'-FAM-TCAGCACGAAGGATGCTGATAACGACA-BHQ2 
Rev: 5'-AGAGCGCATTTGCACATACAG
ANG-2 Fwd: 5’-GCAAGTGTTCCCAGATGCTCT
Probe: 5'-FAM-AGGAGGCTGGTGGTTTGACGCATGT-BHQ2
Rev: 5'-TGTGGGTAGTACTGTCCATTCAAGTT
HPRT Fwd: 5'-GCTCGAGATGTCATGAAGGAGA
Probe: 5'-HEX-CATCACATTGTGGCCCTCTGTGTGCT-BHQ2
Rev: 5'-AGGTCAGCAAAGAACTTATAGCCC
Tie2 Fwd: 5'-ATCACCGTGCTTGTTGGC
Probe: 5'-FAM-CAACTGAAGAGAGCAAATGTCCAAAGGAGA-BHQ2 
Rev: 5'-CACGTTCTGGAATGCCTGAG
VEGF Fwd: 5'-CCCTGGCTTTACTGCTGTACC
Probe: 5’-FAM-ACCATGCCAAGTGGTCCCAGGC-BHQ 1
Rev: 5'-CATGGGACTTCTGCTCTCCTT
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time PCR was carried out using the above cDNA as template. The reaction mixture (50 
pi) contained Ix PCR buffer, 5 mM MgCb, 200 pM dNTPs, Ix ROX dye, 400 nM assay- 
specific forward primer, 400 nM assay-specific reverse primer, 100 nM assay-specific 
dual-labeled probe, and 1.25U Taq polymerase. Thermal cycling conditions for the ABI 
PRISM® 7700 Sequence Detector were as follows: 95°C for 1 min and 40 cycles of 95°C 
for 12 s and 60°C for 30 s. Analysis of raw data was accomplished with the SDS 
software version 1.9 (Applied Biosystems). The data was expressed as a ratio of the 
mean triplicate value of target amplicon (i.e. ANG-1) to the mean value of HPRT.
Data Analysis
Data were expressed as mean +/- standard error of the mean (SEM). Prior to statistical 
analysis, a log 10 transformation was performed on ANG-1 and ANG-2 real-time RT- 
PCR data resulting in a lognormal distribution. For real-time RT-PCR and ELISA data, 
comparisons to NSC were carried out using one-way ANOVA followed by the Dunnett 
post hoc test for multiple comparisons. Two-way ANOVA was run on all data sets to 
obtain the mean square error for post hoc analysis. The mean square error was used to 
calculate the Tukey test for all possible pairwise comparisons between surgical control 
and microcauterizer groups at a given time-point or within microcauterizer groups. Data 
were represented graphically as percentage of NSC; statistical analyses for real-time RT- 
PCR and ELISA were carried out on raw data prior to normalization to NSC. Statistical 
analyses were carried out using SPSS software version 11.0 (SPSS, Chicago, IL), and 
statistical differences were considered significant at p< 0.05.
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MORPHOLOGICAL RESULTS
/3-galactosidase staining o f whole mount infarcted tissue provides a global view o f  
angiogenic growth and remodeling.
Microscopy of Bluo-Gal stained, MC-treated hearts (Fig. 2) revealed an infarct of 
approximately 1.5-2 mm in diameter at all time-points studied. Initial formation of a 
capillary plexus surrounding the infarct area was visible as early as Id post-treatment 
(FT; Fig. 2B). A similar response was observed at 4d FT (Fig. 2C); however, expansion 
of the zone of growth surrounding the infarct had begun to occur. The extent and density 
of the capillary ring progressively increased through 7d FT (Fig. 2D), and vessels of 
increased diameter were also noted in the vaseular network. By lOd FT (Fig. 2E), the 
infarct was completely eovered by neovasculature and both fine capillary vessels and 
larger vessels were evident. At 14d post-infarction (Fig. 2F), a shift in the appearance of 
the vaseulature was evident from the presence of fine microvessels visible at previous 
time-points to exelusively larger vessels. SC tissue (not shown) showed no differenee 
from NSC (Fig. 2A); neither control group demonstrated a vascular response sueh as that 
seen in the MC-treated groups.
Gomori trichrome staining o f heart tissue reveals tissue remodeling in the infarct.
A Gomori trichrome stain of zinc-fixed hearts harvested 4, 7 (Fig. 3B-C), 10, and 
14d (Fig. 4A-B) post-treatment revealed the infarcted area as demonstrated by collagen- 
staining throughout the infaret and distinet staining of intact cardiac muscle outside of the 
wound site. At 4d FT (Fig. 3B) eellular debris, including damaged cardiae musele and 
red blood eells, remained within the infarcted area. Also noticeable was a greater density
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FIGURE 2
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Figure 2. Whole mount P-galactosidase staining of infarcted Tie2LacZ murine heart 
tissue (B-F). Capillary plexus formation around the infarct was evident as early as Id PT 
(B) with broadening of the growth area at 4d PT (C). At 7d PT (D), the capillary ring had 
increased in density and larger vessels had begun to appear. By lOd PT (E), the infarcted 
area was covered by neovasculature and both fine capillary vessels and larger, 
remodeling vessels were evident. At 14d PT (F), the infarct was traversed almost 
exclusively by larger vessels. Surgical control hearts (not shown) showed no difference 
in appearance when compared to non-surgical control (NSC; A). Arrowheads indicate 
representative areas of angiogenic growth. Arrows indicate representative areas of 
remodeling. Bar = 0.5mm
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of cells, as evidenced by nuclear staining, in the periphery of the infaret when compared 
to surrounding uninjured myocardium. Although collagen had been deposited, the infaret 
maintained an unorganized appearance. By 7d PT (Fig. 3C) clearance of cellular debris 
from the infarcted area was essentially complete and the site was characterized by loose 
connective tissue. At lOd post-infaretion (Fig. 4A), the tissue was characterized by an 
increase in larger caliber vaseular structures including a medial layer. In addition, the 
cellular density within the infarcted region was comparable to surrounding uninjured 
tissue. By 14d PT (Fig. 4B), a well-established connective tissue layer characterized by 
dense collagen was visible in the infarct area. Additionally, the site was filled with 
numerous large vessels as evidenced by well-formed medial layers surrounding the 
intima. In lOd and 14d PT tissue, both arterial and venous vessels had formed as 
evidenced by the thickness of medial and adventitial layers surrounding the intima. 
Control vessels in an area of uninjured tissue (Fig. 3A) showed well-formed medial 
layers.
Transition from vascular chord formation to remodeling is demonstrated by PECAM and 
smooth muscle a-actin double-label immunohistochemistry.
Platelet endothelial cell adhesion molecule (PECAM) and smooth musele a-aetin 
(SMA) immunohistochemistry (Fig. 3D-F; 4C-D) revealed distinct labeling of endothelial 
eells by PECAM and both pericytes and smooth musele eells by SMA. At 4d PT (Fig. 
3E), the central area of the infaret was essentially void of PECAM labeling; however, 
numerous PECAM-labeled vaseular chords were visible in the periphery of the infarcted 
region. In addition, diffuse SMA-staining in the central area of the infaret may be
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FIGURES
SI.
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Figure 3. Evidence of vaseular growth in response to mieroeauterizer-treatment at 4d and 
7d PT. Gomori trichrome stain of infarcted Tie2LacZ mouse heart tissue (B-C) 
delineates the infarct with collagen in the infarcted area staining light blue and uninjured 
muscle staining dark red; nuclei are dark purple. Double-label immunohistochemistry for 
smooth muscle a-actin (SMA; red) and PECAM (green) labels smooth muscle 
cells/pericytes and endothelial cells, respectively (D-F). Representative control vessels in 
non-infarcted tissue show strong labeling with both PECAM and SMA (D); the 
corresponding triehrome-stained section is shown (A). Vascular chord formation is 
evident in the periphery at 4d PT (E) with expansion of the vascular response into the 
center of the infarcted area by 7d PT (F). Arrowheads indicate vascular chords and 
microvessels characteristic of the growth response. Arrows designate vessels with 
intimal and medial layers labeled with PECAM and SMA, respectively. Asterisk (*) 
indicates reference vessel for comparison to ANG-2 and phospho-Tie2 immunostaining. 
Representative images are shown. Bar = 50pm
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myofibroblasts. By 7d PT (Fig. 3F) expansion of PECAM-labeled vascular chords and/or 
small caliber blood vessels into the central area of the infarct was evident. At lOd post- 
infaretion (Fig. 4C), large vessels were common throughout the area with stabilization of 
the intima by a SMA-labeled medial layer that varied in thickness and intensity of 
staining. A small number of PECAM-labeled mierovessels remained in the periphery of 
the infarct and had assumed a rounded appearance as compared to the vascular chords 
seen at 4d PT. The infarct tissue harvested 14d PT (Fig. 4D) was predominated by large 
caliber vessels. A well-defined intimal layer stained with PECAM and a developing 
medial layer consisting of tightly packed eells arranged radially was evident. However, 
SMA staining of the medial layer was diffuse compared to mature control vessels (Fig. 
3D). A majority of large vessels seen at both lOd and 14d PT exhibited an irregular 
border demonstrating punctate SMA-labeling as well as weakened PECAM-labeling 
when compared to peripheral microvessels and a small number of large vessels in the 
same infarct.
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Figure 4. Transition to vascular remodeling by lOd and 14d post mieroeauterizer- 
treatment. The infaret is delineated by Gomori triehrome stain of murine heart tissue (A- 
B). Collagen in the site stains light blue, nuclei dark purple, and musele dark red. 
Double-label immunohistochemistry for smooth musele a-aetin (red) and PECAM 
(green) labels smooth musele eells/perieytes and endothelial eells, respectively (C-D). 
Large caliber vessels are evident throughout the infarcted area at both time points. 
PECAM-staining defines the intima whereas medial layers not yet fully established are 
characterized by SMA-labeling of varying intensity. Arrows indieate vessels with a well- 
formed intimal layer and a medial layer demonstrating SMA staining. Arrowheads 
designate vessels showing weakened PECAM labeling as well as irregular borders 
suggestive of vascular regression. Representative images are shown. Bar = 50pm
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mRNA AND PROTEIN EXPRESSION RESULTS
ANG-1, ANG-2, Tie2, and VEGF mRNA expression
In order to better understand the molecular regulation of the morphological 
changes associated with vascular growth and remodeling, mRNA analysis was 
performed. The results of real-time RT-PCR analyses for ANG-1, ANG-2, Tie2, and 
VEGF expression are shown in Fig. 5 (ANG-2, VEGF) and Fig. 6 (ANG-1, Tie2). 
Comparisons between non-surgical control (NSC) and microcauterized (MC) groups 
were carried out using one-way ANOVA followed by the Dunnett post hoc test. Two- 
way ANOVA followed by the Tukey test for multiple comparisons was used to determine 
statistical differences between surgical control and microcauterizer groups at a given 
time-point or within the microcauterizer group. A summary of statistically significant 
differences (p<0.05) resulting from pairwise comparisons is listed in Table 3.
No statistically significant differences were seen when comparing surgical control 
(SC) to infarcted (MC) tissue at any time point for any of the targets measured. A 
biphasic pattern was evident in ANG-2 expression of the MC groups with increases in 
message at 4d and lOd post-treatment (PT) when compared to NSC and Id PT tissue. 
Only the 4d group demonstrated a significant increase when compared to the 7d and 14d 
PT groups. VEGF mRNA levels differed from NSC as well as Id MC at the 4d and lOd 
post-MC time points. ANG-1 mRNA levels were significantly different in the MC group 
with an increase at Id and a decrease at 14d when compared to NSC. In addition, ANG-1 
displayed a similarly biphasic pattern of expression in the MC group with significant 
differences in mRNA at Id, 4d, and lOd PT when compared to 7d and 14d time points.
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An increase in Tie2 message was measurable at lOd post-MC when compared to NSC as 
well as 7d and 14d MC groups.
Western Blot Method Development
In an attempt to characterize the regulatory mechanisms of angiogenesis and 
vascular remodeling at the protein level, Westem blot analyses and ELISA (for VEGF 
only) were carried out. A standard Westem Blot protocol previously used in the Coffin 
laboratory was followed for initial testing of antibodies against ANG-1, ANG-2, Tie2, 
and phospho-Tie2; antibodies from two different manufacturers were tested for ANG-2 
and Tie2. The results demonstrated specific detection of ANG-I, ANG-2, and phospho- 
Tie2; however, non-specific binding was high on both ANG-2 and phospho-Tie2 blots.
In addition, Tie2 was not detected. Consultation with technical support specialists from 
the manufacturers of the ANG-2, Tie2, and phospho-Tie2 antibodies resulted in the 
following recommendations:
1) Dilute antibodies in Tris-buffered saline (TBS) only without dry milk or 
Tween-20 because the detergent may cause the formation of micelles, which may 
interfere with antibody binding
2) Consider testing a different secondary antibody for one of the Tie2 antibodies
3) Consider increasing the concentration of dry milk for blocking and antibody 
dilution
Each of these recommendations was tested individually. Dilution of the antibodies in 
either TBS or TBST without milk resulted in significantly higher background with no 
improvement in specific signal. Similarly, a higher concentration of milk/TBST resulted
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Figure 5. Real-time RT-PCR analyses of ANG-2 and VEGF mRNA expression 
demonstrated significant (p<0.05) increases in both ANG-2 and VEGF at 4d and lOd PT 
compared with NSC (indicated by *). Additional statistically significant differences 
(p<0.05) were seen when comparisons were made within the MC group (Table 3). Raw 
values were normalized to HPRT and expressed as percentage of NSC +/- SEM (n = 8-9 
per sub-group). Hyphenated (— ) line indicates NSC (baseline) expression. MC = 
microcauterizer-treated, SC = surgical control, NSC = non-surgical control, d = days 
post-treatment
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Figure 6. Real-time RT-PCR analyses of ANG-1 and Tie2 mRNA expression relative to 
NSC demonstrated significant (p<0.05) increases in ANG-1 and Tie2 at Id and lOd PT 
respectively and a decrease in ANG-1 at 14d PT (indicated by *). Significant differences 
in ANG-1 or Tie2 message were also noted when comparisons were made within the MC 
group (Table 3). Raw values were normalized to HPRT and expressed as percentage of 
NSC +/- SEM (n = 8-9 per sub-group). Hyphenated (— ) line indicates NSC (baseline) 
expression. MC = microeauterizer-treated, SC = surgical control, NSC = non-surgical 
control, d = days post-treatment
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TABLE 3
Sub-group A Sub-group B ANG-1 ANG-2 Tie2 VEGF
IdM C NSC *
Id SC
4d MC * *
7d MC *
lOd MC * *
14d MC *
4d MC NSC * *
4d SC
IdM C *
7d MC * *
lOd MC
14d MC * *
7d MC NSC
7d SC
IdM C *
4d MC * *
lOd MC * *
14d MC
lOd MC NSC * * *
lOd SC
IdM C *
4d MC
7d MC * *
14d MC * *
14d MC NSC *
14d SC
IdM C *
4d MC * *
7d MC
lOd MC * *
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Table 3. Summary of pairwise comparisons carried out for determination of statistical 
significance. Comparisons between non-surgical control and microcauterizer-treated 
subgroups were made by one-way ANOVA followed by the Dunnett post hoc test. Two- 
way ANOVA followed by the Tukey test for multiple comparisons was carried out to 
determine differences between surgical control and microcauterizer-treated groups at a 
given time-point or between the microcauterizer-treated sub-groups. An asterisk (*) 
indicates a statistically significant (p<0.05) difference when comparing sub-group A and 
sub-group B.
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in slightly higher hackground than the standard eoncentration of 5% milk/TBST. In 
addition, Tie2 remained undetectable with any of the secondary antibodies tested.
Upon further consultation, Pharmingen (maker of one of the Tie2 antibodies) 
technical support suggested that the transfer step may be inadequate; Pharmingen 
recommended an equivalent of 1 Amp for 90 min with a transfer buffer containing 0.05% 
SDS. The extended transfer time (compared to the standard protocol originally used) and 
addition of 0.05% SDS to the transfer buffer were tested independently. Side-by-side 
comparison of blots transferred at lOOV for 5 h to blots transferred at the standard lOOV 
for 2 h demonstrated a specific band corresponding to the Tie2 protein without non­
specific binding only with the 5 h transfer. In addition, the increased transfer time 
combined with further dilution of the antibodies resulted in elimination or improvement 
of non-specific binding for ANG-2 and phospho-Tie2, respectively. Comparison of the 
extended transfer to a transfer at 25 V overnight in the cold showed no difference. 
Addition of 0.05% SDS to the transfer buffer (which can facilitate detection of high 
molecular weight proteins) resulted in improvement of ANG-2 and Tie2 signals. 
Furthermore, Coomassie stain of protein gels post-transfer showed numerous proteins 
remaining in the gel transferred without SDS and virtually no protein in the gel 
transferred with SDS. However, the addition of SDS was detrimental to the quality of the 
ANG-1 and phospho-Tie2 signals. Therefore, Westem blotting for all proteins utilized a 
5 h lOOV transfer with the addition of 0.05% SDS to the ANG-2 and Tie2 transfer buffer 
and no SDS in the ANG-1 and phospho-Tie2 transfer buffer.
In an effort to further reduce non-specific signal detected by the phospho-Tie2 
antibody, blocking of the membrane and dilution of the antibodies was carried out in 10%
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BSA/TBST rather than 5% milk/TBST. The modification resulted in improved signal 
intensity with a relatively minor increase in non-specific binding. Use of 10%
BSA/TBST for ANG-2 and Tie2 blots resulted in loss of specific signal and an increase 
in background without a significant increase in specific binding, respectively. Therefore, 
membrane blocking and dilution of antibodies was carried out in 10% BSA/TBST for 
phospho-Tie2 blots and 5% milk/TBST for ANG-1, ANG-2, and Tie2 blots.
Following final optimization of antibody dilutions using the transfer and blocking/ 
dilution conditions described above, an initial set of ANG-1 and phospho-Tie2 blots was 
run on two sets of pooled tissue. In addition to ANG-1 and phospho-Tie2, the blots were 
probed with anti-actin to establish equal loading. Densitometric analysis of the actin 
bands demonstrated appreciable changes between the sub-groups. Later investigation 
showed that the anti-actin antibody that had been used detected all forms of actin rather 
than P-actin alone. The other housekeeping gene commonly used as a loading control, 
GAPDH, was eliminated as a candidate due to its regulation by hypoxia inducible factor 
(HIF)-l. Upon further consultation, p-tubulin was selected for testing. At a very high 
antibody concentration, only a faint band corresponding to P-tubulin was detected, 
therefore use of the protein as a loading control was not feasible.
The next alternative considered was Ponceau staining for total transferred protein; 
Ponceau staining of the membrane is the equivalent of Coomassie staining of a gel. 
Ponceau staining was attempted on several test blots but proved ineffective because 
wetting the blot to obtain an image for quantification caused rapid fading of the protein 
bands. The final method tested for assessment of equal loading of total protein was 
MemCode™ Reversible Protein Stain commercially available from Pierce. MemCode'^’̂
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is a total protein stain similar to Ponceau but is considered more sensitive and does not 
exhibit the problematic fading associated with Ponceau stain. In practice, bands 
designating proteins detected by the MemCode stain faded but did so less rapidly than 
Ponceau stain allowing sufficient time to capture an image. However, numerous methods 
of densitometric analysis resulted in highly variable results suggesting that the utility of 
MemCode™ as a loading control is questionable. Because of the inability to identify a 
reliable loading control for the current experiments, the data were considered to be more 
representative without normalization to a loading control. Repeated protein assays on a 
proportion of the samples to confirm protein concentrations, as well as previously 
established accuracy of pipetting technique, facilitated estahlishment of equal loading 
without the use of a true loading control.
Analysis o f ANG-1, ANG-2, Tie2, phospho-Tie2, and VEGF protein levels
VEGF ELISA results and Westem blot analyses for ANG-1, ANG-2, Tie2, and 
phospho-Tie2 are depicted in Fig. 7 (ANG-1, ANG-2), Fig. 8 (Tie2, phospho-Tie2), and 
Fig. 9 (VEGF). No statistically significant differences were seen when comparing SC to 
MC tissue at any time point for any of the proteins assayed. In addition, no significant 
change in protein expression was noted for ANG-1, Tie2, phospho-Tie2, or VEGF 
proteins. Determination of the ratio of phospho-Tie2 to Tie2 protein for each suh-group 
also showed no change across the time course. Although not statistically significant, 
ANG-2 demonstrated a steady decrease in protein expression from Id through 14d post­
treatment. A second group of blots could not be analyzed statistically due to inadequate 
sample number but showed similar trends to the data presented. The lack of changes in
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expression for any of the proteins studied was in contrast to the significant differences 
demonstrated by mRNA analysis when comparing between NSC and MC sub-groups and 
within the MC group.
Immunostaining Method Development
To assess possible changes in protein expression patterns that may not have been 
reflected in the quantitative data, immunostaining of tissue sections was attempted. A 
standard immunostaining protocol previously used in the Coffin laboratory was followed 
for initial testing of antibodies against ANG-1, ANG-2, Tie2, and phospho-Tie2 in tissue 
fixed in Tris-buffered zinc fixative (Tris/zinc). With the exception of staining of red 
blood cells (RBCs) in all tissue sections, no-primary controls for ANG-2 and phospho- 
Tie2 demonstrated a lack of non-specific staining; however, goat anti-human ANG-1 and 
mouse anti-human Tie2 antibodies showed significant levels of background. Tissue 
immunostained for either antibody had been blocked with normal horse serum (NHS); 
therefore, a new lot of NHS was diluted and tested. Non-specific staining was evidenced 
with serum from either batch suggesting that the blocking step was not the cause of the 
background staining.
The anti-Tic2 tested was a mouse monoclonal antibody, which suggested that 
binding of the secondary antibody to endogenous mouse immunoglobulin may have 
resulted in non-specific staining. Therefore, a commercially available mouse-on-mouse 
blocking kit was tested with the anti-Tic2 primary antibody. While treatment of the 
tissue to block mouse immunoglobulin did reduce background, non-specific staining was
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Figure 7. Westem blot analyses of ANG-1 and ANG-2 demonstrated no temporal change 
in protein expression. Densitometry values were normalized to NSC from the same blot 
prior to calculating mean and expressed as percentage of NSC +/- SEM (n = 4). 
Statistically significant differences were not seen when comparing SC and MC groups at 
a given time-point or MC groups across the time course (p<0.05). Hyphenated (-—) line 
indicates NSC (baseline) expression. MC = microcauterizer-treated, SC = surgical 
control, NSC = non-surgical control, d == days post-treatment
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Figure 8. Westem blot analyses of Tie2 and phospho-Tie2 showed no temporal change 
in protein expression. Densitometry values were normalized to NSC from the same blot 
prior to calculating mean and expressed as percentage of NSC +/- SEM (n = 4).
Statistical differences were not seen when comparing SC and MC groups at a given time­
point or MC groups across the time course (p<0.05). Hyphenated (— ) line indicates 
NSC (baseline) expression. MC = microcauterizer-treated, SC = surgical control, NSC = 
non-surgical control, d = days post-treatment
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Figure 9. VEGF protein expression showed no change over time when assessed by 
ELISA. Values were expressed as percentage of NSC +/- SEM (n = 4). Statistical 
differences were not seen following multiple comparisons (p<0.05). Hyphenated (— ) 
line indicates NSC (baseline) expression. MC = microcauterizer-treated, SC = surgical 
control, NSC = non-surgical control, d = days post-treatment
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not eliminated nor was specific staining detected. A biotinylated anti-Tic2 was also 
tested on the Tris/zinc fixed tissue and demonstrated no specific staining.
Antigen-retrieval techniques were not performed as part of the ANG-1 and Tie2 
protocols; however, the relatively fragile nature of the Tris/zinc fixed tissue compared to 
paraformaldehyde fixed tissue precluded the use of pepsin & trypsin treatments longer 
than 3 min or citrate/heat treatment. In addition, previous immunostaining of 
paraformaldehyde fixed tissue with the ANG-1 goat anti-human antibody showed no 
staining with or without antigen retrieval. Testing of a second ANG-1 antibody on 
Tris/zinc fixed tissue also demonstrated no specific staining.
Diaminobenzidine-only treatment of Tris/zinc fixed tissue sections showed 
reactivity of RBCs suggesting that the standard peroxidase-blocking treatment was 
inadequate. A battery of peroxidase-blocking techniques was tested and treatment of 
tissue sections overnight in 0.3% H2O2/40% MeOH in PBS was found to successfully 
block the endogenous peroxidase activity of the red blood cells; the addition of this 
blocking step to the immunostaining protocol eliminated non-specific staining 
(previously seen in RBCs) in no-primary controls for ANG-2 and phospho-Tie2. 
Unsuccessful peroxidase-blocking techniques included 3% H2O2/ H2O for 10 min, 0.3% 
H202/Me0H for 20 min, 100% EtOH followed by 0.075% HCl for 15 min, and 0.01% 
periodic acid for 10 min followed by 0.1 mg/ml sodium borohydride for 2 min. ANG-2 
and phospho-Tie2 were carried out following the standard protocol with the replacement 
of the 10 min 3% H2O2/H2O treatment with incubation overnight in 0.3% H2O2/40% 
MeOH in PBS.
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Angiopoietin-2 Immunohistochemistry
Angiopoietin (ANG)-2 immunohistochemistry on infarcted tissue (Fig. 10) 
showed no notable change in labeling within the wound site when comparing 4d, 7d, lOd, 
and 14d PT hearts. Positive cells were visible within the infarct at each time point; 
however, no change in the pattem of expression was clearly discernible. In addition, no 
vessels within the wound site demonstrated positive labeling around the entire 
circumference of the vessel at any time-point. Similar staining of cells and vessels was 
seen in non-infarcted tissue (at all time points) and NSC. ANG-2 immunostaining 
showed no appreciable differences in staining patterns within or between groups 
consistent with the results of Westem blot analysis for the protein.
Phospho-Tie2 Immunostaining
Immunostaining for phosphorylated Tie2 (Fig. 11) revealed distinct pattems of 
expression in the infarcted region at each of the time points studied. At 4d PT (Fig. 1 IB) 
numerous cells, microvessels, and vascular chords exhibited positive staining for 
phospho-Tie2 in the periphery of the injured tissue; however only a few positive cells or 
microvessels were seen in the center of the infarct. Examination of 7d PT tissue (Fig.
11C) showed immunostaining resembling that of the 4d tissue, however positively 
stained vessels were seen throughout the wound site. In addition, anti-phospho-Tie2 
positive vessels of increasing diameter were also noted. At lOd post-infarction (Fig.
1 ID), staining was seen throughout the infarcted area with vascular chords, micro vessels, 
and vessels of small diameter demonstrating the most intense reactivity. Large-caliber 
vessels within the infarct showed weak or no phospho-Tie2 reactivity. Phospho-Tic2
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labeling of 14d infarcted tissue (Fig. 1 IE) revealed minimal staining of the large vessels 
that dominated the site; positive staining did not cover the entire circumference of the 
vessels and was often weak. Phospho-Tie2 staining of cells and vessels of various 
diameters, especially microvessels, was also seen in non-infarcted tissue (Fig. 1 lA) at all 
time points. In contrast to the quantitative Westem data, phospho-Tie2 immunostaining 
demonstrated changes in expression between the time-points suggesting that the 
differences in pattems of expression may have resulted in no net change in phospho-Tie2.
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Figure 10. Alternate serial seetions were immunolabeled for angiopoietin (ANG)-2 at 4, 
7, 10, and 14d post-microcauterizer-treatment. Comparison of staining from each time­
point (B-E) showed no difference in expression pattem. Similar ANG-2 staining of cells 
and occasional vessels was seen in surgical control (A) and non-surgical control (not 
shown) tissue. Arrows indieate ANG-2 positive cells; arrowheads designate vessels 
positive for ANG-2. Asterisk (*) indicates referenee vessel for comparison to trichrome 
staining. Infarct area in (C) is region below line; non-infarcted myocardium is above the 
line. Representative images are shown. 400X magnification; inset = lOOOX 
magnification
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Figure 11. Immunolabeling of infarcted tissue for phospho-Tie2 demonstrated 
differences in expression pattem between the time-points. Numerous positively-labeled 
micro vessels and chords are seen at 4 (B), 7 (C), and lOd (D) PT with progression of the 
vessels from the periphery at 4d post-infarction into the center of the infarct area by 7d 
PT. Large-caliber vessels at 10 and 14d (E) PT indicate weak phospho-Tie2 labeling. 
Phospho-Tie2 staining of micro vessels, chords, cells, and partial staining of larger vessels 
was also seen in surgical control (A) and non-surgical control (not shown) tissue. Arrows 
indicate phospho-Tie2 positive micro vessels, vascular chords, and cells. Arrowheads 
designate vessels demonstrating relatively weak phospho-Tie2 immunoreactivity.
Asterisk (*) indicates reference vessel for comparison to trichrome staining. Infarct area 
in (C) is region below line; non-infarcted myocardium is above the line. Representative 
images are shown. 400X magnification; inset = lOOOX
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DISCUSSION
Cardiovascular disease is the cause of death of almost 1 million individuals in the 
United States each year^. Reduction in blood flow due to coronary artery disease results 
in deprivation of oxygen and nutrients to the myocardium causing severe tissue damage. 
The development of novel and effective therapeutie angiogenesis strategies is contingent 
upon understanding the regulation of angiogenesis and vascular remodeling in the adult 
heart. Previous research has demonstrated that the mechanisms regulating these 
processes are complex and multi-factorial, though not clearly defined. Furthermore, 
models attempting to characterize the roles of angiogenic regulatory molecules often fail 
to plaee these factors within a morphologically defined model of vascular growth and 
remodeling. Placement of regulatory data within the framework of a well-characterized 
angiogenic model will significantly strengthen its contribution to the design of rational 
therapeutie strategies. The overall objectives of this study were to characterize the 
transition between angiogenesis and vascular remodeling during tissue remodeling in the 
isehemic murine heart and establish temporal expression patterns of the angiogenic 
regulatory molecules ANG-1, ANG-2, Tie2 receptor, VEGF, and the phosphorylated 
Tie2 receptor within the context of a model of vascular growth and remodeling.
Angiogenesis and Vascular Remodeling in the Infarcted Murine Heart
The ability to morphologically assess the complete angiogenic response, 
comprised of both growth and remodeling phases, is a key factor in determining the
 ̂American Heart Association. Heart Disease and Stroke Statistics -  2004 Update. Dallas, Tex.: American 
Heart Association; 2003.
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regulatory mechanisms of each aspect of the process. Tie2LacZ transgenic mice provide 
an attractive experimental system for histologically defining angiogenic growth and 
remodeling. Microcauterizer-treatment of the heart to generate a myocardial infarction 
serves as a means of stimulating a complete angiogenic response. Tissue remodeling 
associated with the microcauterizer-generated infarct is consistent with that evidenced in 
a murine model of myocardial infarction induced by permanent left anterior descending 
coronary artery occlusion [76]. Whole mount P-galactosidase staining of the tissue 
provides a global view of morphological changes in the vasculature. Unlike previous 
systems using fluorescein-dextran perfusion of the whole mount heart [75], the Tie2LacZ 
model allows detection of microvessels surrounding the infarct as early as Id PT with 
growth most readily visible at 4d and 7d PT. In addition, early signs of vascular 
remodeling are evident at the 7d time-point in contrast to the fluorescein-perfused heart 
in which an apparently avascular area was noted at 7d PT. The Tie2LacZ model shows 
gross evidence of remodeling at lOd and 14d PT with the presence of a substantial 
number of larger vessels traversing the infarct area. In addition, the presence of larger 
remodeled vessels and a small number of fine micro vessels at lOd PT, suggests a 
transitional phase between growth and remodeling.
The whole mount data is further substantiated by PECAM and smooth muscle a- 
actin (SMA; for smooth muscle cells and pericytes) labeling of infarcted tissue from each 
time point. Bluo-Gal staining was determined to be the preferred method for whole 
mount characterization of the tissue; however, based on preliminary studies and a 
published report which found PECAM immunohistochemistry to be superior to P- 
galactosidase staining of sectioned cardiac tissue [91], the former method was selected
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for the current study. The appearance of PEC AM-labeled vascular chords in the 
periphery of the 4d PT infarct is consistent with the early Bluo-Gal stained capillary 
plexus surrounding the infarcted region. Furthermore, the broadening of the vascular 
zone around the damaged area and initial appearance of larger vessels at 7d PT is 
consistent with the expansion of PEC AM-stained microvessels into the central area of the 
infarct. The large Bluo-Gal stained vessels crossing the infarcted area at lOd PT 
correspond with the relative increase in large caliber, PECAM-labeled vessels within the 
site, which in addition to SMA staining surrounding the vessels, suggests a transition to 
early maturation and stabilization of the neovasculature. Additionally, the decreased 
PECAM-staining of large vessels and irregular vascular borders seen at lOd and 14d PT 
raises the possibility that vascular regression may also be taking place as part of the 
remodeling process. Regression is believed to occur in part through endothelial cell 
apoptosis [7,11], which would result in an apparent reduction in PECAM-staining. 
Remodeling of infarct-specific neovasculature is most predominant at 14d PT as 
evidenced by the large Bluo-Gal stained vessels traversing the site as well as the 
prevalence of double-labeled vessels when studied in cross-section.
The proposed time course for angiogenesis and vascular remodeling is consistent 
with a report by Sephel et al in a study of basement membrane components in wound 
angiogenesis [93]. In the space-filling sponge implant model, capillary growth was 
observed between days 3 and 5 with maturation by day 12, as indicated by lumen 
diameter. Furthermore, a maturation phase extending from 14 days post-occlusion was 
described in a rabbit hind-limb model of collateral growth [94]. While the model 
proposed by Scholz et al delineates the cellular and proteolytic activity taking place
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during the maturation phase, it does not describe the remodeling process in terms of 
stabilization of vascular structure. A number of other models also describe the 
expression of a variety of molecular signals and the activity of specific cell types, 
including endothelial and smooth muscle cells, over a period of time [95-98]. However, 
while these models suggest a time course for the angiogenic process, little emphasis is 
placed on the importance of vascular remodeling in this process.
Remodeling results in the pruning, stabilization, and maturation of the vascular 
network. To this point, the focus of therapeutic angiogenesis strategies has remained 
primarily on the stimulation of new blood vessel growth. While an increase in the 
number of vessels may be a necessary element of collateral cireulation formation, the 
remodeling process has been a frequently overlooked component that may in fact be 
essential to the development of effective angiogenic therapies in the heart. Gene therapy 
using angiogenic factors to stimulate coronary angiogenesis has become a highly 
desirable means of treating cardiovascular disease. However, in order to provide long­
term benefits, therapeutic angiogenesis strategies must result in patent, functional vessels 
that increase the overall perfusion of the affected area. Using Tie2LacZ mice, we have 
described the morphological changes characteristic of angiogenesis and the transition to 
vascular remodeling. This model allows the ability to selectively study time-points 
demonstrating desired characteristies of growth or remodeling in vivo enabling a more 
focused analysis of the regulatory mechanisms controlling a specific aspect of the overall 
process. For example, a focus on the 4d time-point would enable a better understanding 
of the specific cellular mechanisms involved in regulating the formation of new vessels 
on the periphery of a myocardial infarction prior to scar formation.
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mRNA Expression o f ANG-1, ANG-2, Tie2, and VEGF
Existing therapeutic angiogenesis strategies have focused primarily on the VEGF 
and fibroblast growth factor families, due largely to their ability to stimulate angiogenesis 
in animal models and in vitro. A number of gene and protein therapy studies utilizing 
these factors have demonstrated increases in perfusion and improvement in angina or 
objective measures of function. Nonetheless, side effects, such as edema, and yet to be 
answered questions about long-term stability of the neovasculature have led to the 
hypothesis that a single growth factor may not be adequate to stimulate the development 
of a stable, functional vasculature capable of effectively perfusing the target tissue. As a 
result, additional factors, including ANG-1 and HIF-la, are under investigation. In 
addition to other favorable characteristics, in vivo models utilizing either factor have 
stimulated a vascular response without the leaky vessels attributed to VEGF-stimulation 
of vascular permeability [71, 72]. However, the selection of these factors for therapeutic 
angiogenesis has been based largely on knowledge gained from non-cardiac systems, 
such as embryonic development, the skin, and in vitro studies. Knowledge of 
mechanisms regulating angiogenesis and vascular remodeling in the mammalian heart 
will facilitate the refinement of therapeutic strategies for myocardial ischemia.
In order to better understand the molecular regulation of the morphological 
changes associated with vascular growth and remodeling, real-time RT-PCR was 
performed to assess ANG-I, ANG-2, Tie2, and VEGF mRNA levels. The real-time data 
suggest a possible role for the ANG/Tie2 system and VEGF in establishment and 
maturation of the neovasculature. Comparison of infarcted tissue to NSC showed 
significant increases in ANG-2, Tie2, and VEGF mRNA at lOd PT corresponding to the
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transition to remodeling demonstrated morphologically. A rise in ANG-1, although not 
achieving statistical significance, was also evident at the lOd time-point. In addition, 
significant increases in ANG-2 and VEGF were also demonstrated at 4d PT suggesting a 
potential role for these factors in the growth of the neovasculature. These data suggest 
that the ANG/Tie2 and VEGF systems could be involved in coordinately regulating the 
growth and later stabilization of the newly formed vasculature.
A coordinate role for ANG-2 and VEGF in vascular growth and/or remodeling 
has been previously suggested based on a variety of evidence. Coexpression of ANG-2 
and VEGF has been noted at sites of angiogenesis, including the corpus luteum and 
vascularized tumors [48, 65]. In addition, stimulation of ANG-2 expression by VEGF 
has been demonstrated in vitro [47]. In vivo administration of ANG-2 with VEGF results 
in a proangiogenic effect in comeal micropocket and pupillary membrane models [54, 
66]. Furthermore, ANG-2 and VEGF protein levels peaked at 3d post-treatment in a 
canine model in which animals were subjected to repetitive episodes of myocardial 
ischemia by brief occlusion of the left anterior descending artery (LAD) [77]. The 
similar biphasic expression pattems of ANG-2 and VEGF mRNA noted in the current 
study combined with evidence from prior studies provides support for a role of these 
factors in the vascular response to cardiac ischemia.
A critical concern regarding the RNA expression data is the lack of significant 
differences between microcauterizer-treated and surgical control tissue at any time-point 
for any of the factors studied. The morphological changes described provide clear 
evidence that a difference does exist between the microcauterizer-treated and surgical 
control tissue. The essential question is whether changes in expression between NSC and
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MC groups or between time-points within the MC groups are relevant in light of the 
surgical control data.
Existing evidence suggests that hypoxia, which has been shown to stimulate 
VEGF, ANG-2, and Tie2 expression in vitro, may be induced by thoracotomy alone [99]. 
In addition, the thoracotomy itself is likely to trigger a wound-repair response, which 
includes angiogenesis, as a result of the incisions made to the skin and muscle. While 
growth factors are known to act on a local, rather than systemic, level, it is conceivable 
that activation of cytokines and other circulating factors by thoracotomy, or more 
specifically the wound healing response, may result in up- or down-regulation of local 
angiogenic factors elsewhere in the thorax.
Additional evidence suggests that an increase in growth factor expression alone is 
not sufficient to stimulate vascular growth. Intramuscular gene transfer of VEGF DNA 
into ischemic limb resulted in neovascularization only in the ischemic limb in spite of 
elevated serum VEGF levels and edema in the non-ischemic limb [69]. These data 
suggest that a local hypoxic stimulus, or other insult, must be coupled with modulation of 
growth factor expression to trigger an angiogenic response; this information is consistent 
with the lack of vascular response in the SC animals in spite of elevation of growth factor 
levels over NSC. Therefore, changes in mRNA expression, potentially resulting from 
thoracotomy, may integrate with biochemical changes triggered by mieroeauterizer- 
treatment of the heart to initiate the vascular response evidenced morphologically. The 
following experimental plan is designed to elucidate a potential mechanism for the up-or 
down-regulation of angiogenic factors in the heart following thoracotomy.
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Experimental Plan fo r  Analysis o f the Affect o f Thoracotomy Treatment
The quantitative mRNA and protein data presented suggest that the surgical 
control treatment stimulates changes in expression of angiogenic factors in the heart. 
Opening of the chest wall causes a wound healing response characterized by both 
inflammation and angiogenesis. This response is believed to stimulate circulating 
factors, such as cytokines, which may cause downstream effects in the cardiac tissue. 
Based on previous studies demonstrating stimulation of angiogenesis and/or regulation of 
angiogenic factors [79, 100-102], TNF-a, IL-6, and IL-8 are candidates for modulating 
the expression of angiogenic factors in response to thoracotomy. The proposed aims will 
test the hypothesis that thoracotomy initiates a change in angiogenic factor expression in 
the heart by stimulation of circulating cytokines, such as tumor necrosis factor (TNF)-a, 
interleukin (IL)-6, and IL-8.
Specific Aim I: Establish protein expression profiles o f circulating TNF-a, IL-6, 
and IL-8 following thoracotomy. Tie2LacZ transgenic mice will undergo thoracotomy 
only, and serum will be collected prior to thoracotomy and at 1,4, 7, and 10 days post­
treatment prior to sacrifice at day 10; serum will also be collected from age-matched non- 
surgical control mice. ELISA will be used to measure serum protein levels of each 
cytokine. A significant increase or decrease in serum levels of any of the cytokines 
studied compared to non-surgical mice will suggest that thoracotomy treatment stimulates 
inflammatory response involving said factor; such factors will be investigated further in 
Aim II. No change in the expression profile of TNF-a, IL-6, or IL-8 suggests that these 
factors are not stimulated in the circulation following thoracotomy but does not preclude 
the involvement of other circulating cytokines.
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Specific Aim II: Determine the effect o f cytokines identified in Aim I  on VEGF, 
ANG-1, ANG-2, and Tie2 mRNA levels in vitro. Real-time RT-PCR for VEGF, ANG-1, 
ANG-2, and Tie2 will be used to quantify changes in mRNA expression following 
treatment of a vascular smooth muscle cell/endothelial cell co-culture with recombinant 
cytokine (i.e. TNF-a); eytokine(s) demonstrating up- or down-regulation in the serum of 
animals from Aim I will be assessed in vitro. Subsequently, angiogenic factor expression 
will be assessed following administration of cytokine and anti-cytokine receptor antibody 
to block signaling of the protein. TNF-a, IL-6, or IL-8 is expected to stimulate an 
increase in mRNA expression of VEGF, ANG-1, ANG-2, and Tie2 in smooth muscle and 
endothelial cell co-culture. Addition of anti-eytokine receptor antibody is expected to 
block the increase demonstrating that the change in mRNA is cytokine-dependent. An 
increase in angiogenic factor expression in spite of the administration of blocking 
antibody will suggest that the change is cytokine-independent and may in fact be due to 
up-regulation of one of the other angiogenic factors.
Specific Aim III: Assess the effect o f disruption o f cytokine signaling on ANG-1, 
ANG-2, VEGF, and Tie2 mRNA levels in vivo. Investigation of cytokines in Aim II will 
be continued in Aim III. Prior to thoracotomy treatment, Tie2LacZ transgenic mice will 
be injected systemieally with anti-eytokine receptor antibody; non-surgieal controls will 
also be injected with the blocking antibody. In addition, a species-specific isotype 
control antibody will be injected prior to thoracotomy treatment to ensure the effects seen 
in the primary treatment group are not caused by immunoglobulin molecules. Serum will 
be collected from all groups prior to antibody injection and at 1,4, 7, and 10 days post­
injection to monitor circulating cytokine levels. ELISA will be used to assess serum
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protein levels of the cytokine. In the thoracotomy and control groups receiving the 
blocking antibody, a decrease in circulating cytokine is likely to result from autocrine 
feedback mechanisms. No change in cytokine expression should be seen in the isotype 
control group. At 10 days post-injection, heart tissue will be harvested from all groups, 
and ANG-1, ANG-2, VEGF, and Tie2 mRNA levels assessed by real-time RT-PCR. No 
change in ANG-1, ANG-2, VEGF, or Tie2 mRNA levels is expected in the hearts of 
animals receiving blocking antibody prior to thoracotomy treatment upon comparison to 
non-surgical controls. Messenger RNA levels of angiogenic factors in the heart should 
be stimulated in the isotype control as seen in prior experiments. A change in angiogenic 
factor expression in the heart following thoracotomy, in spite of disruption of signaling of 
the targeted cytokine, would suggest that one or more different circulating factors may 
act to initiate downstream changes in the heart or that the mechanism for modulation of 
angiogenic factors following thoracotomy is cytokine-independent.
ANG-1, ANG-2, Tie2, and Phosphorylated Tie2 Protein Analysis
In an attempt to characterize the regulatory mechanisms of angiogenesis and 
vascular remodeling at the protein level, ELISA for VEGF and Western blot analyses for 
ANG-1, ANG-2, Tie2, and the phosphorylated Tie2 receptor were carried out. However, 
the changes in expression evident by real-time RT-PCR were not reflected in the protein 
data. While the use of the NSC as a blot-to-blot normalization standard precluded 
statistical comparison of Western blot data from microcauterized samples and NSC, 
graphical interpretation of the data suggested no difference. Furthermore, comparisons 
within the MC group showed no significant differences suggesting the concept that
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neither the VEGF nor the ANG system is involved in the modulation of vascular growth 
and remodeling associated with the microcauterizer-generated infarct.
Several possible explanations may account for the disparity between the RNA and 
protein data. First, the growth factors analyzed may not play the predominant role in this 
system. While a broad range of in vivo and in vitro studies provides support for the 
involvement of the VEGF and ANG/Tie2 systems in vascular growth and remodeling, 
previous cardiovascular studies have not provided consistent evidence for a clearly 
defined role of any of these factors or receptors in the formation and remodeling of 
vasculature in the adult heart. The likelihood that the role of these factors is system and 
context dependent is highlighted by the disparity in results when comparing similar 
cardiovascular models. The canine repetitive occlusion model demonstrated an increase 
in ANG-1 mRNA at 2 Id of repetitive occlusion with a decrease in ANG-2 at the same 
time-point [77]. In contrast, a rat model of permanent LAD occlusion showed no change 
in ANG-1 mRNA but an increase in ANG-2 at three weeks post-infarction [78].
In addition, an essential difference between the current study and the occlusion 
models described is the use of time-point surgical controls. Both Matsunaga et al and 
Shyu et al compared infarcted tissue to a single time-point surgical control rather than a 
control at each time-point [77,78]. As seen in Fig. 5, 6, and 9, apparent differences in 
expression between time-points and between NSC and MC grpoups are raised into 
question when the SC for that time-point is considered. Therefore, the possibility exists 
that the interpretation of the data from Matsunaga et al and Shyu et al may have been 
altered if time-point surgical controls had been included in the studies.
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An alternative explanation for the lack of detectable changes in protein expression 
over time is the limitations of the methods used to quantify such differences. While the 
VEGF ELISA may detect as little as 5 pg VEGF per 1 ml total protein, the technique 
specifically measures only the VEGF-164 isoform. A previous study using real-time RT- 
PCR to detect total VEGF mRNA and the VEGF-164 ELISA showed an increase in total 
mRNA expression compared to non-transgenic littermates, but no corresponding increase 
in VEGF protein expression [71] consistent with the current study. Additional studies 
have demonstrated differential regulation of the VEGF isoforms [103-105]. Together, 
these findings suggest that assessment of only VEGF-164 protein may not reflect changes 
in total VEGF protein expression. In addition, the sensitivity of Western blotting varies 
from protein to protein and is highly dependent on a number of factors, including transfer 
of proteins from gel to membrane and antibody specificity and sensitivity. For the 
ANG/Tie system. Western blot analysis may have limited utility as a quantitative method 
to detect small changes in protein expression.
Post-transcriptional regulation of the factors and receptor in question is a third 
possible explanation for the lack of change in protein levels. Little is known about the 
post-transcriptional regulation of any of the molecules investigated in this study.
Hypoxia has been shown to mediate VEGF expression by increasing stability of the RNA 
[29, 30]. While previous evidence has demonstrated stimulation of ANG-2 and Tie2 by 
hypoxia, post-transcriptional regulation of the angiopoietins and their receptor is 
currently unknown.
Finally, the Western blot and ELISA analyses showed no quantitative differences 
in ANG-1, ANG-2, Tie2, phospho-Tie2, or VEGF protein. However, this does not
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exclude the possibility that the proteins of interest may be expressed by only a small 
subset of cells, which may be diluted by excess tissue from within or outside of the 
infarcted region. This hypothesis was tested by immunohistochemical analysis of 
sectioned tissue containing the infarcted area.
Immunohistochemical Analysis o f ANG-2 and phospho-Tie2
Equally important as the quantity of a given protein is the spatial distribution of 
that protein. In order to ascertain whether changes in protein expression across the time 
course were non-existent or not measurable by Western blot or ELISA, immunostaining 
was attempted for ANG-I, ANG-2, Tie2, and phospho-Tie2. Labeling for ANG-I and 
Tie2 were unsuccessful with the antibodies tested therefore the tissue distribution of these 
proteins remains undetermined in this system.
While ANG-2 immunolabeling was successful, comparison of infarcted tissue 
within the MC group or against non-infareted tissue showed no appreciable differences in 
staining pattems. These findings confirm the lack of measurable differences between SC 
and MC tissues by Westem blot. The immunostaining data suggest that significant 
differences at the mRNA level seen when comparing within the MC group may not have 
been translated into protein changes due to post-transcriptional regulation. In addition, 
consistent with the observations of Ray et al [73], ANG-2 expression appears to be 
localized to the smooth muscle layer of vessels rather than the vascular endothelium.
This finding suggests that information acquired from in vivo and in vitro studies 
demonstrating ANG-2 expression by endothelial cells may be of limited use in 
understanding the role of ANG-2 in the cardiac vasculature.
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Consistent with prior data [43], vessels exhibiting positive immunolabeling for 
phosphorylated Tie2 were seen throughout the heart. However, the expression, most 
evident at 4d and 7d, of phospho-Tie2 by vascular chords and micro vessels generated in 
response to microcauterizer-treatment suggests a further role for the Tie2 system in the 
vascular response to infarction. Previous in vivo data have suggested a role for ANG- 
1/Tie2 in maturation and stabilization of vessels by recruitment of perivascular support 
cells [53, 54]. However, the progression from angiogenesis to vascular remodeling 
evidenced morphologically suggests that microvessels seen at the 4d and 7d time-points 
are unlikely to be supported by pericytes or smooth muscle cells. While the ANG-1/Tie2 
system may play a role in temporary stabilization of newly formed vessels, an altemative 
function may be the promotion of endothelial cell migration and tube formation. In vitro 
evidence has shown that treatment of ECs with ANG-1 results in both a chemotactic 
response [49, 50] and tubule formation [51]. Additionally, an anti-apoptotic effect has 
been demonstrated for ANG-1 acting via Tie2 [40,49-52] suggesting that activation of 
the Tie2 receptor may protect newly formed vessels from undergoing premature 
regression prior to completion of remodeling.
Furthermore, the phospho-Tie2 immunostaining provides evidence that the 
localization of the protein and/or organization of cells expressing the activated receptor 
may prove of greater importance than the measurable quantity of the protein. As with 
ANG-2, the expression of phospho-Tie2 throughout the heart tissue may explain the 
absence of a quantitative difference in expression when microcauterized tissue was 
compared to surgical controls. However, there is a clear difference in the pattern of 
expression when examining the infarct of 4, 7, 10, and 14d tissue suggesting that
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rearrangement of cells and/or vessels positive for activated Tie2 may result in no net 
change in phospho-Tie2. In addition, while ANG-1 has been shown to induce migration 
and EC survival via PI3-kinase pathways, the signaling pathways leading to putative 
perivascular cell recruitment and tube formation are currently unknown [106, 107]. This 
suggests the possibility that unknown permissive stimuli may result in a shift in the 
downstream signaling of the cell avoiding the need for an increase in the overall amount 
of ligand or receptor.
Revised Model for Regulation o f Angiogenesis and Vascular Remodeling
The proposed model, shown in Fig. 12, has been refined to reflect the data 
obtained through these experiments. While Westem blot and ELISA analyses showed no
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changes in ANG-1, VEGF, and total Tie2 expression, the model indicates putative roles 
for ANG-1 and VEGF, which will be discussed in detail below. In addition, the role of 
Tie2 is based on the results of the phospho-Tie2 immunostaining, as the effects of the 
receptor are believed to require prior autophosphorylation.
While a small number of in vitro studies have demonstrated that ANG-2 may 
stimulate phosphorylation of Tie2 under unique conditions [48, 62, 63], immunostaining 
for ANG-2 suggests that is unlikely in this model given the distinct pattem of expression 
compared to phospho-Tie2. In addition, the ANG-2 Westem blot and 
immunohistochemistry indicate that ANG-2 is not involved in destabilization of the 
existing vasculature as proposed, or any other aspect of the angiogenic response to 
microcauterizer-generated infarction at the time-points studied.
While VEGF ELISA analysis did not demonstrate differences in expression of the 
VEGF-164 isoform at any of the time-points studied, the possibility exists that the 
VEGF-120 or -188 isoforms may be elevated as a component of the vascular response. 
Prior evidence for differential expression of VEGF isoforms following myocardial 
infarction was provided by semi-quantitative RT-PCR analysis of rat cardiac tissue. 
Relative levels of the VEGF-120, -164, and -188 isoforms varied at the time-points 
studied, with VEGF-120 and -188 demonstrating greater change over time than VEGF- 
164 [105]. Furthermore, significant evidence suggests a role for VEGF in vascular 
formation.
The ability of VEGF to stimulate endothelial cell proliferation and migration has 
been extensively documented in vitro [19,22]. In addition, numerous studies have shown 
changes in VEGF expression associated with myocardial ischemia/infarction [77, 78, 80].
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Protein and gene therapy studies in myocardial and critical limb ischemia have routinely 
demonstrated increases in capillary density and improvement in hemodynamic measures 
in response to VEGF administration providing evidence that the growth factor can indeed 
stimulate neovascularization [69, 72, 81-85]. The studies described combined with the 
limitations of the methods used to detect VEGF protein expression in this study suggest 
that VEGF may still play a role in angiogenic growth.
While a change in ANG-1 protein expression was not quantifiable by Westem 
blot analysis, this does not preclude a role for the growth factor in the vascular growth 
and remodeling evidenced morphologically. As previously discussed, ANG-1 is the only 
known ligand for Tie2 capable of consistently stimulating autophosphorylation of the 
receptor. This strongly suggests that ANG-1 immunostaining would mimic the pattems 
of phospho-Tie2 expression seen in the microcauterized and control tissue. As with 
phospho-Tie2, the localization of the protein and/or pattem of expression may be of 
greater significance than the quantity of the protein.
Previous studies have suggested a direct role for ANG-1/Tie2 in recmiting 
smooth muscle cells and/or pericytes to the vascular endothelium to facilitate maturation 
of the vessel. However, the model depicted in Fig. 12 proposes that activation of Tie2 by 
ANG-1 may instead stabilize the vascular endothelium, inhibiting permeability and 
promoting endothelial cell survival, providing a permissive signal for reemitment of 
perivascular support cells by other factors, such as platelet derived growth factor (PDGF). 
This hypothesis is supported by data from a postnatal murine retinal model. Systemic 
administration of an anti-PDGF receptor-P antibody blocked mural cell reemitment to the 
developing retinal vasculature [89]. Injection of exogenous ANG-1 into the vitreous
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cavity restored the hierarchical organization of the vasculature and rescued vascular 
edema but was not capable of stimulating perivascular cell recruitment in the absence of 
PDGF signaling. Furthermore, this data supports a role for ANG-1/Tie2 in tube 
formation and differentiation of the vasculature into a network of vessels of varying 
diameter; the involvement of ANG-1 in formation a hierarchical network was first 
suggested by the phenotype of the ANG-1 null mouse [53]. Finally, previous models 
have suggested that binding of ANG-1 to Tie2 may stimulate the release of factors 
responsible for the recruitment of perivascular cells to the immature vasculature [44, 53]. 
However, to this point, no such factors have been identified providing further evidence 
that the ANG-1/Tie2 system may be involved in stabilizing the vascular endothelium 
rather than in the direct recruitment of mural cells.
Potential Improvements in the Experimental Design
While the Tie2LacZ microcauterizer model has allowed morphological 
determination of a transition from angiogenesis to vascular remodeling, several potential 
improvements in the model should be considered. Utilization of a LAD occlusion model 
would eliminate possible questions regarding the impact of generating an infarct with a 
heat probe. As previously mentioned, the tissue remodeling resulting from 
microcauterizer-generation of the infarct is equivalent with that following LAD 
occlusion. However, destruction of tissue and cauterization of vessels in this manner 
may initiate distinct wound responses, which may inhibit or promote additional factors 
involved in the process of neovascularization. In the same regard, it is impossible to
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distinguish between tissue response(s) that may be resulting from the infarct and those 
from the bum trauma.
In addition, the LAD model, while not capable of eliminating biological 
variability inherent in an in vivo system, would enhance the consistency of the infarct in 
terms of both placement and severity. While every effort was made to achieve 
consistency in microcauterizer-generation of the infarct, a number of factors affected the 
depth and diameter of the infarct and where the infarct was generated on the left ventricle 
of the heart. Ideally, the infarct was generated on the apical left ventricle; however, 
biological variables, ineluding situation of the heart in the chest cavity and rate of 
heartbeat, typically caused variation in the exact placement of the wound. In addition, 
the battery-operated microcauterizer was manually controlled therefore the heat of the 
cautery tip and steadiness of the operator’s hand, as well as the biological variables 
already mentioned, may have led to variation in the length of time the tip was in contact 
with the tissue, which may in tum have affected the depth and diameter of the infarct. 
Even slight differenees may coneeivably have resulted in greater deviation in the results 
of the biochemical analysis of the tissue. While the precise anatomy of each mouse is 
unique, placement of the LAD ligature around the same portion of the vessel would likely 
result in greater consistency than the current method [108].
A further consideration is the method of harvesting the tissue for RNA and 
protein biochemistry. The eurrent method of extracting a 3 mm punch of tissue was 
designed to reduce dilution of RNA or protein changes within the infarct by non-infarcted 
tissue. However, several factors may lead to increased deviation in the results. First, the 
location of the infarct and plane of bisection generates variability in the quantity of tissue
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harvested. Because the placement of the infarct is unique from heart to heart, bisection of 
the heart followed by tissue pimch may result in unequal amounts of non-infarcted tissue 
captured within the punch.
Two possible alternatives have been demonstrated in rat myocardial infarction 
models. The first is dissection of the left ventricle to the interventricular septum [78]. 
While the size of the dissected left ventricle will vary from animal to animal, the 
technique should result in increased consistency of the amount of damaged relative to 
undamaged tissue. The second option is dissection of the infarcted area away from the 
uninfarcted tissue. Li et al demonstrated the ability to separate the tissue based on visual 
appearance of the heart muscle [80]. For either altemative, the possibility exists that the 
size of the murine heart relative to the rat heart may preclude use of the method.
A third consideration is quantitative assessment of ANG-1, ANG-2, Tie2, 
phospho-Tie2, and VEGF protein levels. While ELISAs are known to be a more specific 
and sensitive method of assessing protein expression, their development, with the 
exception of VEGF, is currently hindered by availability of murine-specific antibodies.
As antibodies become available, ELISAs can be developed following the protocol of 
Chong et al [109]. In addition, antibodies against altemative epitopes, such as those 
containing tyrosine 992 or a second antibody containing tyrosine 1108 may confirm 
phospho-Tie2 expression. Finally, use of a VEGF ELISA capable of detecting all 
isoforms of the protein will enable quantification of changes in total VEGF protein 
expression.
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In summary, the regulation of angiogenesis and vascular remodeling is a complex, 
multi-factorial process, involving a delicate balance between a variety of inducers and 
inhibitors of the process(es) [110]. Understanding the interplay between these factors in 
a specific in vivo system is necessary to effectively exploit the roles of these molecules in 
a therapeutic setting. Furthermore, determination of temporal expression pattems of 
angiogenic regulatory factors will facilitate combinatorial or sequential administration in 
the treatment of cardiac hypoxia. A well-characterized angiogenic model also provides 
opportunities for the identification of yet unknown factors, such as those suggested in 
Fig. 12, which may be critical to the regulatory cascade. The results presented 
demonstrate that the angiogenic response following microcauterizer generation of an 
infarct in the Tie2LacZ mouse provides a histologically and temporally defined model for 
the study of vascular growth and remodeling processes in the heart in addition to the 
characterization of the regulatory pathways mediating these phases. The results of the 
angiopoietin/Tie2 and VEGF expression studies reiterate the potential complexity of 
determining the specific roles of these factors in the adult cardiac vasculature. 
Furthermore, the data show the need for additional research into the growth/remodeling 
transition with greater emphasis on the role of remodeling in coronary angiogenesis.
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